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Abstract
BODY COMPOSITION USING AIR DISPLACEMENT PLETHYSMOGRAPHY IN
OBESE ADULTS: EFFECT OF ESTIMATED VERSUS MEASURED THORACIC GAS
VOLUME
Jayvaughn T. Oliver
B.S., Appalachian State University
Chairperson: Jonathon L. Stickford, Ph.D.
Introduction: The Bod Pod uses air displacement plethysmography (ADP) to measure
body volume (Dempster, 1995), and, with the measurement of body mass, is able to
calculate body density for the analysis of body composition. However, total body
density will be incorrectly estimated if the gas volume within the lungs at the time of
the body volume measurement, termed thoracic gas volume (VTG), is measured
inaccurately. The Bod Pod can account for VTG by using a prediction equation based
on age and height (VTGpred), or by direct plethysmographic measurement (VTGmeas).
It is well established that obesity (OB) alters operational lung volumes at rest, which
has the potential to increase the error associated with VTGpred and the corresponding
estimation of body composition. The purpose of this study was to examine the effect
of VTGpred and VTGmeas on estimates of body fat percentage (%BF) using the Bod
Pod (%BFVTGpred, and %BFVTGmeas, respectively) as compared to %BF from dual X-
ray absorptiometry (DXA) and a subcomponent estimation from DXA, trunk fat
percentage, in normal weight (NW) and (OB) adults. Methods: Subjects came to the
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lab for a single visit and body composition testing was performed via Bod Pod and
DXA. 15 NW (22.2 ± 1.7 kg·m-2) and 9 OB (32.1 ± 1.9 kg·m-2) adults (24 ± 6 yr)
participated in the study. A mixed design analysis of variance was used to examine
the effects of group and method on measurements of VTG and %BF. Results: The
group by method interaction (F1,22 = 3.017, p = 0.096, η2 = 0.11), the main effect for
method (F1,22 = 2.330, p = 0.141, η2 = 0.09), and the main effect for group
(F1,22 = 3.685, p = 0.068, η2 = 0.14), were not significant for VTG. The differences
between VTGpred and VTGmeas were not significantly related with body mass index
(BMI) (r = 0.33, p = 0.11) but were with trunk fat percentage (r = 0.47, p = 0.02).
There was a significant group by method interaction for %BF (F2,44 = 10.060,
p = 0.001, η2 = 0.46). Additionally, the main effect for group with %BF was
significant (F1,22 = 10.944, p = 0.003, η2 = 0.51). However, the main effect for method
with %BF was not significant (F2,44 = 0.663, p = 0.479, η2 = 0.03). The differences
between VTGpred and VTGmeas were significantly related with the differences between
%BFVTGpred and %BFVTGmeas (r = 0.92, p < 0.001). In conclusion, although this study
is underpowered, there appears to be a relationship between differences in VTG and
error of %BF estimation. The differences of VTG is significantly related with the fat
that is carried around the chest. DXA also appears to estimate %BF lower in normal
weight adults but higher in obese adults compared to ADP.
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Introduction
Overview
Obesity is generally defined as an excess amount of adipose tissue (Gadde, 2018). A
more phenotypical trait of obesity is the large variation of body fat distribution relative to the
total body mass (Thomas, 2012). While not a direct measure of body fat, body mass index
(BMI) provides an index of fatness by scaling body weight relative to height. Adults with a
BMI ≥30 kg·m-2 are considered obese, which is calculated using the following equation:= ( ) • ℎ ℎ( ) (1)
The prevalence of obesity has increased substantially across the United States (US)
over the past 20 years, with over 100 million adults currently classified as obese (Hales,
2017). The growing prevalence of obesity has reached epidemic status resulting in over 147
billion dollars annually in medical expenses (Finkelstein, 2009). The relationship between
all-cause mortality and body weight is not entirely clear (Ades, 2010); however, those who
are obese are known to be at higher risk for a variety of health conditions such as
cardiovascular disease, type 2 diabetes, and respiratory complications (Bastien, 2014;
Beuther, 2006; Hubert, 1983). Thus, it is imperative that obese individuals lose weight in
order to reduce the potential negative health consequences and ease the substantial economic
burden.
A variety of methods exist to help individuals lose weight, including: changes in
dietary behaviors, engaging in regular exercise routine, and participating in pharmacological,
and or surgical treatments (Santos, 2017). In 2017, nearly 44% of US adults engaged in at
least one weight loss strategy (Santos, 2017). Measuring changes in body composition is a
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useful method to track the effectiveness and progress in those trying to lose weight.
However, obesity can sometimes prove to be an obstacle in the accurate estimation of body
composition because equipment used for measurement cannot always accommodate larger
body sizes, and some assumptions that these devices make based on normal populations do
not apply to obese individuals.
Common methods of estimating body composition aim to measure the amount of fat
mass (FM) versus fat free mass (FFM) that make up the body (Fields, 2002; Lee, 2008). This
two-part approach is known as the two-compartment model, and uses the densitometric
method by categorizing body composition based on the inherently different densities of FM
and FFM. Air displacement plethysmography (ADP) is a favored method of body
composition estimation in many populations due to its relative ease of use, and ability to
comfortably accommodate larger individuals. Dual X-ray absorptiometry (DXA) further
separates FFM into bone and lean tissue constituents while still accounting for FM. Thus,
DXA is considered a more robust measure of estimating body composition compared with
ADP because it can separate tissues into three, as opposed to two compartments.
Air Displacement Plethysmography
Use of ADP in obese individuals is practical because it requires little technical skill,
and can accommodate larger individuals (Bernhard, 2016). By measuring body mass and
volume, density can be determined. While mass is typically measured by a scale, ADP
measures volume by the displacement of air. Subsequently, the calculated density is used to
estimate percent body fat (%BF). To more precisely estimate body composition based on
volume, factors that have the potential to alter body volume measurements are important to
consider. For air displacement devices, the volume of gas within the thoracic cavity, termed
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thoracic gas volume (VTG), plays an important role in the accuracy of body volume
measurements.
The ADP device can predict or measure average lung volumes during tidal breathing
within the chamber. In normal weight adults, the predicted and measured VTG (VTGpred and
VTGmeas respectively) are similar to one another, along with the respective estimates of %BF
using VTGpred and VTGmeas (D. Wagner, 2015). Yet, there still are gaps in knowledge with
how these two methods compare in obese adults, whose lung volumes at rest are different
than normal weight adults of the same height and age. Wagner (2015) analyzed the
agreement of these methods in athletes and observed that the subjects with the smallest VTG
had their VTG overestimated and those with a higher VTG had their VTG underestimated.
This may suggest that obese adults who demonstrate lower operational lung volumes at rest,
may have less consistent findings between VTGpred and VTGmeas.
Dual X-ray Absorptiometry
DXA is a method of measuring body composition using photon absorptiometry. The
device relies on the core concept that X-ray light will be attenuated as a function of the tissue
it passes through (McCrory, 1998b; Pietrobelli, 1996). DXA is a popular tool that often can
be found in many research and clinical settings, making it useful in comparing body
composition in epidemiological studies (Cornier et al., 2011). While DXA can provide more
robust measurements to estimate body composition, similar to ADP, it is still limited by the
assumptions regarding the density of human tissue. The benefit of DXA in contrast to ADP is
that measures for estimating %BF are independent of VTG. DXA cannot be substituted for a
gold standard such as the four-compartment model, but its broadened use in clinical and
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research practice serves as an anchor to compare other accessible methods of body
composition measurement.
Summary
Statement of the Problem
It is unknown whether estimation VTG by VTGpred will be different in obese adults,
and if those potential differences will contribute to greater error in the %BF estimations
compared to VTGmeas in obese adults compared to normal weight adults. By understanding
the impact that obesity may have on %BF estimates, more care can be taken by researchers
and clinicians to ensure the most reliable techniques are being implemented for estimating
%BF by ADP in an obese population.
Purpose of the Study
The primary purpose of the study was twofold: 1) to examine VTGpred and VTGmeas in
obese (OB) and normal weight (NW) adults and 2) to examine the %BFVTGpred and
%BFVTGmeas in OB and NW adults. A secondary purpose was to compare %BF estimates
obtained via Bod Pod with an estimate obtained via DXA, a lung volume independent
technique.
Delimitations
The study was delimited by the following:
1. Males and females between the ages of 18 and 45 years participated.
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2. All doors to the room with Bod Pod remained closed during calibration and
testing in an effort to minimize air flow (Lowry & Tomiyama, 2015).
3. The Bod Pod and DXA devices were calibrated the day of each visit.
4. All subjects wore minimal skin tight garments along with a swim cap in an
effort to minimize surface area artifact (SAA) for the Bod Pod.
5. All subjects wore the same garments for DXA as for the Bod Pod to maintain
consistency across methods of measurement.
6. Height of the subjects was measured to the nearest centimeter.
7. Weight of the subjects was measured to the nearest kilogram.
8. All of the subjects voided their bladder before the test
9. All of the subjects completed tests back to back
10. All of the subjects refrained from exercise in the two hours prior to testing.
11. All of the subjects fasted two hours before the visit.
Limitations
Interpretation of the results should consider the following limitations:
1. All of the subjects were from the same geographical area.
2. Some subjects had facial hair and/or body hair not accounted for with
skintight gear.
3. Skintight garments will make up some of the measured mass of the individual.
4. The Bod Pod assumes uniform density of FFM.
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Research Question
The primary research question was to examine the potential differences in VTGpred,
and VTGmeas, and the respective calculations of %BF in OB compared with NW adults. The
secondary research question was to examine %BF via ADP (%BFVTGpred, %BFVTGmeas) with
%BF from DXA (%BFDXA). The following research questions were addressed:
1. Are VTGpred and VTGmeas significantly different in OB and in NW adults?
2. Are the differences between VTGpred and VTGmeas significantly associated
with BMI?
3. Are %BFVTGpred and %BFVTGmeas significantly different in OB and NW adults?
4. Are %BFVTGpred, %BFVTGmeas, and %BFDXA significantly different in OB and
NW adults?
5. Are the differences between VTGpred and VTGmeas significantly related with
the differences between %BFVTGpred and %BFVTGmeas in OB and NW adults?
Hypotheses
The primary hypotheses of the study are:
1. VTGpred and VTGmeas will be significantly different in OB adults but not in NW
adults.
2. The differences between VTGpred and VTGmeas will be significantly associated
with BMI.
3. %BFVTGpred and %BFVTGmeas will be significantly different in OB adults but not in
NW adults.
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4. %BFVTGpred, %BFVTGmeas, and %BFDXA will be similar in NW adults; %BFVTGpred,
%BFVTGmeas, and %BFDXA will be significantly different in OB adults, with
%BFVTGmeas similar to %BFDXA in OB adults.
5. The differences between VTGpred and VTGmeas will be associated with the
differences between %BFVTGpred and %BFVTGmeas in OB and NW adults.
Definition of Terms
Obesity- Excess amount of body weight for a given height (Wellens, 1994).
Air Displacement Plethysmography- The measure of volume via the displacement of air
(Aitkens, 1995).
DXA- Machine that measures the attenuation of high and low energies of X-rays passing
through the body to evaluate body composition (Toombs, 2012).
Body Mass Index- A ratio of one’s mass to their height squared (Wellens, 1994).
Thoracic Gas Volume- Volume of air within the lungs at the end of a tidal breath (D.
Wagner, 2015).
Forced Vital capacity- Maximal volume of air that can be exhaled after a forced exhalation
(Robert Crapo, 1994)
Forced Expiratory Volume in 1 second- Maximal volume of air exhaled, after a maximal
inhalation, in the first second of a forced exhalation (Robert Crapo, 1994).
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Literature Review
Obesity is an Epidemic
Obesity is defined as having an excess accumulation of body mass in respect to one’s
height. It is increasingly prevalent in affluent societies that are living in dietary excess
(Kopelman, 2000). Within the US alone, over one-third of the population is now considered
to be overweight. The prevalence of obesity has increased drastically over the past 50 years
(Kuczmarski, 1994; Ogden, 2015).
The National Health and Nutrition Examination Survey (NHANES) reported in 2017,
that the prevalence of obese adults over 20 yr has reached 39.6%. That percentage applied to
national health estimates in 2017 from the United States Census Bureau (2017 National
Population Projections Datasets, 2018), projected 96 million adults 20 yr or older in the
United States would be considered OB. That is not even considering that over 18% of the
youth (ages 2-19 yr) are now OB with significantly increasing trends (Hales, 2017). Obesity
has become so prevalent, that it is now affecting the economic health of the nation.
The economic cost of obesity is a public health concern. There is a link between
obesity, and medical spending. Those who are obese are at an increased risk for
cardiovascular disease, type 2 Diabetes, along with various respiratory complications
(Bastien, 2013; Chan, 1994; Zammit, 2010). As of 2008, aggregate medical cost of obesity
was estimated to be up to 147 billion dollars, representing 9.1% of all annual medical
spending (Finkelstein, 2009).
In epidemiological studies the most common tool for measurement is BMI.
It is a useful method to classify weight status amongst large populations and make valuable
comparisons within and between populations. BMI classification is also advantageous in
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identifying large groups who are at higher risk of morbidity and mortality. The idea behind
the BMI formula is based on the assumption that the varying weight of people of the same
height is generally due to changes in FM (Kopelman, 2000). The current standard of the cut-
off points for the classification of those overweight were suggested by the world health
organization (WHO) experts. They identified two different grades of being overweight.
These two levels are described as preobese, and obese, which can be subdivided into obese
class I, II, and III in order of least to most severe. The cut-off points for each are 25.0-29.9
kg∙m-2, 30.0-34.9 kg∙m-2 35.0-39.9 kg∙m-2, and ≥40 kg∙m-2 respectively (Wellens, 1994).
While there are high associations between increases of BMI and increased risk for
disease, the consequence of obesity is more directly related to fat tissue, and the overall
distribution of that fat tissue in the body (Kopelman, 2000). For example, an increase in FM
will increase the total amount of blood volume, and subsequent amount of oxygen that the
body consumes increasing cardiac output, placing added stress on the heart (Bastien, 2013).
A study done by Krotkiewski et. al., highlighted the differences in regional distribution of
adipose tissue within males and females. Men predominately have more abdominal adiposity,
while women have more peripheral distribution of fat (gluteal and femoral regions). Males
were more likely to indicate signs of metabolic disease, such as higher levels of fasting
glucose and triglycerides. Females with regional adipose tissue similar to the male group
showed similar increases in metabolic disruption (Krotkiewski, 1983). With increases in
FM, there are uniform increases of visceral fat. The increase of this intra-abdominal visceral
adipose tissue (upper body obesity) that is common in men, contributes to organ and
hormone dysfunction. Respiratory complications arise from the distribution of fat that
accumulates around the thoracic cage, and abdomen (Kopelman, 2000; Krotkiewski, 1983)
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Respiratory Complications in Obesity
Increases of BMI are associated with decreases in lung function and lung volumes
(Koenig, 2001a; Mejbel, 2016; Zammit, 2010). A case control study recruiting 100
individuals ages 18-45 yr found significant spirometric reduction in the overweight males
and females. Significant negative correlations were observed with %BF and forced vital
capacity in 1 second (FEV1) (−0.772 p < 0.001), and with %BF and forced vital capacity
(FVC) (−0.869 p < 0.001) (Mejbel, 2016). This decrease in lung function and lung volume
is, in part, due to the accumulation of fat within the anterior chest and abdominal wall
(D'Angelo, 1999; Kopelman, 2000). A cross-sectional population based study was carried out
with a sample of 121,454 men and women (45.7 ± 12.3 yr) in Paris to investigate the risk of
lung function based on characteristics of metabolic syndrome. In their findings those with
larger waist circumferences were at higher odds for impaired lung function (Leone, 2009).
Respiratory Compliance
Obesity contributes to a large load being placed on the respiratory muscles. The
respiratory muscles have to compensate for the extra load contributed by excess fat in order
for alveolar ventilation to be maintained (Sampson, 1983). A prevailing atypical lung volume
measurement across multiple studies involving obese subjects is a decrease in expiratory
reserve volume (ERV) (Koenig, 2001b; Littleton, 2012). These evident decreases in lung
function can be explained in part by the lengthened duration of respiratory muscle activation
during exhalation, and the effect of upper adipose tissue on respiratory mechanics. Whereas
adipose tissue will compress around the thoracic cage, diaphragm, and lungs, negatively
affecting total respiratory compliance. Compliance can be defined as the ratio of change in
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pressure to changes in volume (Suratt, 1984). A decreased compliance of the respiratory
system would indicate that a given change in pressure would change the volume of gas in the
lungs less (Suratt, 1984). Total respiratory compliance is equal to the sum of chest wall
compliance and lung compliance (Harris, 2005). A decreased total respiratory compliance in
obesity is thought to have dynamic contributions from each of these parts. A significant
decrease in the pressure volume curve slop indicated in Figure 1, relates directly with a
decrease in total respiratory compliance.
Figure 1. The effect of obesity on the pressure volume curve; Pst, static pressure of the total
respiratory system; ∆V, change of volume (Harris, 2005).
How is Body Composition Measured?
The term body composition encapsulates multiple subunits of differentiated tissues and
organs, such that the total body mass will equal the sum of these individual parts. Ideally, each
constituent, or compartment, needs to be taken into consideration to accurately account for
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body composition. Given the complexity of the human body, it proves difficult to itemize, and
quantify each individual piece of this larger puzzle (Wang, 1999; Ward, 2018). With
technological advances, more of these constituents can be quantified for application to better
describe the total body composition. More refined methods are not cost effective and require
more training to use. As a result, the two compartment model approach to measurement is
popular.
The methods to measure body composition have greatly changed over the years. There
are multiple techniques used to electronically estimate body fat: bio-electrical impedance
(Bernhard, 2016), DXA, quantitative human tomography, ADP, magnetic resonance imaging,
quantitative magnetic resonance, 3-dimensional photonic scanners, and positron emission
tomography (Lee, 2008). A relatively more practical method of quantifying body composition
is through ADP, this method is more mobile, and reduces subject and technician error
(Dempster, 1995). The derived density of the whole body can be used to estimate a two-
compartment model of body composition (FM and FFM) (Siri, 1961). The density of the
human body can be derived by the relation between its’ mass and volume (2)= ( )/ ( ) (2)
While mass is easily measured, the volume of the body is more difficult to determine.
Body volume is not uniform throughout; cavities within the lungs and gastrointestinal tract are
unable to be detected through superficial measurements of volume. Heat leaving the body also
has potential to alter pressure measurements during ADP. Not correcting for the volume of air
within your body will greatly affect the subsequent calculations of density. Methods for
controlling these variables usually are constringent, and can sometimes be a deterrent for
subject participation, especially when measurements are conducted in water. New technology
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has opened different avenues for collecting accurate measurements that also take less effort for
the subject, and leave less room for technician error. The use of Bod Pod for plethysmography
has grown in popularity because it can provide accurate measurement of density and is a
convenient tool for technicians and patients to use.
The Bod Pod utilizes ADP to indirectly measure body volume. When an individual
sits inside a closed chamber, the amount of air within said chamber will be displaced because
of the addition of a new volume inside the chamber. The volume of air displaced will be
equal to the volume of the body entering the closed system. The Bod Pod measures the
pressure change initiated by a volume perturbing diaphragm while the subject is within the
chamber (Aitkens, 1995). Past methods of ADP required isothermal conditions to measure
volume by pressure, this applies the basic principles of Boyle’s law that states pressure and
volume have an inverse relationship, such that as volume increases, pressure will decrease,
given that temperature does not change. Keeping thermal conditions constant during body
density measurement proves to be a laborious task (Fields, 2002). The Bod Pod makes use of
both Boyle’s gas law and Poisson’s law, which allows for air to expand and compress within
the closed chamber and still have volume and pressures accurately measured. This technique
is useful to account for the increase in temperature that introducing a human subject to the
chamber will cause. As a result, being able to compensate for changes in temperature,
measurements can be assessed with less effort (Dempster, 1995; D. R. Wagner, 2000).
The Bod Pod consist of one structure with two coinciding chambers (front and rear)
which sizes are about 450 L and 300 L respectively. The front chamber is where the subject
is housed. The second chamber is separated by the molded seat in which the subject sits on
during the testing. The rear chamber houses electronics, pressure transducers, breathing
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circuits, valves and the diaphragm that initiates volume perturbations (Figure 1) (Aitkens,
1995). The relations of volume and pressure are applied to measurement when the subject
has been placed in the front chamber, and the door has been sealed by multiple
electromagnets. A diaphragm in the rear chamber oscillates in the positive and negative
direction at a magnitude of about 350 mL inducing pressure changes of about 1 cmH2O
within the system (Aitkens, 1995). Volume will have a linear relationship with these pressure
changes.
Figure 2. Diagrammatic representation of the main components of the Bod Pod system from
the Official Journal of American College of Sports Medicine (Aitkens, 1995).
In order to accurately measure body volume, it is important to account for factors
such as clothing, SAA, and lung volumes (Aitkens, 1995; Fields, 2002; Higgens, 2001;
McCrory, 1998a). The raw body volume (BVraw) that is measured using pressure-volume
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relationships is corrected taking into consideration SAA and VTG. Effects of clothing and
hair are mitigated by the standard use of minimal skin-tight gear and a swim cap. Other
bodily hair may be worth noting in error of measurements (Higgens, 2001). Body surface
area, given a person’s height and weight is estimated using the Dubois formula (Bois, 1916).
The estimated body surface area is then multiplied by a constant that defines the effect
surface area has on volume measurement. The product of these factors gives a correction for
SAA. VTG is either predicted with an estimation equation based on age, and height, or
directly measured with plethysmographic techniques. The formula to determine body volume
includes these factors: = − + 40% (3)
Where BVcorr is corrected body volume, BVraw is raw measurement of body volume based
from Boyle’s law, and 40% of VTG is considered because air within the lungs is considered
isothermal and is 40% more compressible than adiabatic air within the chamber. All values
are expressed in liters (Dempster, 1995; McCrory, 1998a).
Thoracic gas volume may be obtained from the Bod Pod by an estimation equation or
through an actual lung volume measurement within the Bod Pod. VTGpred is calculated for
the Bod Pod as: = + 0.5 (4)
Where functional residual capacity (FRC) is the volume of air within the lungs at the end of a
passive breath. During normal breathing, the amount of air moving in and out of the lungs is
tidal volume (Vt). The mid-point of an exhalation is measured, the 50% of measured Vt the
average volume of air being displaced during normal breathing. The following equations
developed by (R. Crapo, Morris, Clayton, & Nixon, 1982), are how FRC and VTG were
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estimated accounting for age and height. In order to develop prediction equations, multiple
linear regressions of each lung volume were generated against combinations of the
independent variables height, age, and weight SAA. Regression equations were also
calculated using transformations of both the independent and dependent variables. For each
equation, the standard of the estimate and the correlation coefficient were calculated. For the
equations reported, residuals (measured value minus predicted value) were graphically
analyzed by comparing the residual values with the independent variables and the predicted
dependent variables.
Bod Pod is a type of body density measurement. There is a wide variations of body
composition values dependent of the methods of measurement that is utlized, although some
of this difference may be accounted for by biological variability and technical precision, it is
widely unknown as to why these values are different (Fields, 2002).
Average Thoracic Gas Volume
ADP can measure body volumes, and VTG. The value for VTG continuously changes
during the act of breathing (inhalation, exhalation). FRC is described as the volume of gas in
air at the end of a passive exhalation. The amount of volume in the lungs during resting, tidal
breathing ranges from FRC to volume at the end of an inhalation, end inspiratory lung
volume (EILV) (Wanger, 2005). Advanced body composition measurements devices such as
ADP estimate VTG using a regression equation created from healthy, non-smoking adults (R.
Crapo et al., 1982). Accounting for the lung volumes better depicts the density of an
individual after pressure displacement (Aitkens, 1995). Individuals’ who’s lung volumes are
lower relative to others that are their same sex, age, and height are inaccurately depicted by
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these regression equations (Minderico, 2008; D. Wagner, 2015).  For example, an obese
individual will have a smaller FRC and subsequent ERV; the estimated equation that is based
on age and height (R. Crapo et al., 1982), will not account for smaller VTG due to added
adiposity. With this overestimation of FRC in obese individuals, ADP may estimate the
volume of during the measurement incorrectly, and therefore the measured %BF would
potentially be different.
VTG Measurement
The technique the Bod Pod uses to measure thoracic gas volume is based on the
relation between pressure and volume while temperature is constant (Dempster, 1995).
Boyle’s law states that pressure and volume have an inverse relationship (5)= (5)
where P1 is the pressure at FRC, V1 is FRC, and P2 is the pressure at the end of a pant and V2
is the acquired lung volumes (Dubois, 1956; West, 1999). When the subject initially comes
onto the mouthpiece, lung volumes are unknown, without any flow the pressure of alveolar
gas and atmospheric pressure are the same. This is only true if the glottis is open and the
cheeks are held rigid (so they do not puff) If the subject was to voluntarily expire, which
would compress the gas, the difference in pressure would describe the changing lung
volumes during panting at the time of measurement, according to Boyle's law. One way to
measure lung volume is to have the subject inhale after the end of a normal expiration when
the closed system has been occluded and perform a panting maneuver; this is the method the
Bod Pod uses to measure VTG. This method is usually preferred because it allows for
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retracing of the changes in volume and has less change in intrathoracic pressure (Dubois,
1956).
Dual Energy X-ray Absorptiometry
In the study of body composition, DXA is a common device utilized in research
(Pietrobelli, 1996). It is often used to diagnose osteoporosis, osteopenia, and other bone
diseases (Laskey, 1996; Sartoris, 1989; Toombs, 2012). Generally speaking, DXA machines
measure the attenuation of high and low energies of X-rays passing through the body. The X-
rays are comprised of photon particles that are transmitted via electromagnetic energy.
Attenuation of the X-ray is dependent on the intensity of the photon particles, and the density
of the substrate it is passing through. For example, bone mineral (higher density) will have
larger decreases of photon intensity compared to soft tissue (lower density) as it passes
through the body (Pietrobelli, 1996). To determine bone mineral density, DXA software
assumes a compartment model where the body is divided into bone mineral, and soft tissue
(skin, fat, muscles, fluids etc.) (Toombs, 2012). To differentiate between these two
compartments, two intensities of X-rays are used. Low density material attenuates the X-ray
less because more photon particles can pass through the body, the opposite is true for denser
bone mineral. These relationships are used to differentiate between bone mineral density, fat
mass, and fat free mass (Pietrobelli, 1996). The Hologic manufactured DXA performs its
measurements by scanning the body with X-rays that are rapidly switching from high and
low intensities sourced from below the scanning table (Laskey, 1996). The attenuated
photons are detected and measured above the subject being scanned (Figure 2). Although the
main purpose of the DXA has been in quantifying bone density, due to advances in detecting
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changes of photon intensity as it is attenuated through the body, resolution of images has
improved (Toombs, 2012). With improved resolution DXA has also gained the ability to
delineate between other subdivisions of body composition such as FM and FFM.
Figure 3. DXA measures X-rays passing through the body at high and low energies. The X-
ray source is located below the subject, and the attenuation is measured by the detector
hovering over the table (Toombs, 2012).
For the purpose of this study, DXA is appropriate to compare with %BFVTGpred and
%BFVTGmeas. ADP is a two compartment model of estimating body composition dividing
body composition into FM and FFM based on measurements of density (Siri, 1961). Volume
plays an important role in determining density. The assumptions made by the Bod Pod
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software to account for lung volumes does not represent outliers well, especially if an
outlying variable can change the Bod Pod’s software calculation for body volume (effect of
SAA or VTG). As a result, the assumptions used by VTGpred have to be carefully considered
before choosing whether it is appropriate. Measures can potentially be inaccurate for
individuals who deviate from the constants that the devices are fundamentally based on
(Kohrt, 1995; D. Wagner, 2015). This can potentially also be true in terms of accuracy of
estimating lung volumes in an obese population, who tend to breathe at lower than normal
operational lung volumes (Salome, 2010).
A benefit of DXA in comparison to ADP is that estimates of body composition are
independent from measures of lung volumes (Smith-Ryan, 2017), and it does not use density
to predict body fat. Although the trueness of the measurement of body composition using
DXA has promise in the future, it still is debated whether or not it can be considered a
reference standard (Kohrt, 1995; Laskey, 1996; Pietrobelli, 1996; Shiel, 2018). Despite these
disagreements, DXA is a commonly used tool in research that yields accurate and precise
measurements of soft tissue (Svendsen, 1993). The body composition of pigs were measured
using DXA, then with chemical analysis after postmortem homogenization, the respective r
value for the comparison was > 0.97 with a SEE < 3% (Svendsen, 1993). ADP has often
been compared to DXA and showed high correlations within several populations (Ballard,
2004; Levenhagen, 1999; Nunez, 1999; Radley, 2005). ADP is an attractive method to
estimate body composition due to its ease of use, and its ability to accommodate larger body
volumes; it is important to see how these two common tools of measuring body composition
compare with one another.
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The state of obesity is a well-known complication for estimates of body composition
with both ADP and DXA. Densitometry via ADP assumes a constant FFM hydration and
density (Brozek, 1963; Siri, 1961). In an obese population these assumptions can be
inaccurate due to unequal distribution of fluids and adiposity throughout the body (Brozek,
1963; Siri, 1956, 1961; Waki, 1991). The ratio of attenuation between a high energy photon
beam and low intensity photon beam can be used to identify components within the body.
Hydration status can skew the resulting r values of soft tissue, which can change the result of
the subsequent FM. For example, an addition of 1 kg of extra cellular fluid to the reference
man could result in a 0.6% underestimation of body fat (Pietrobelli, 1996). Ideally, the more
compartments that are not assumed, the more accurate the resulting measurements will be
(Smith-Ryan, 2017). However more detailed methods to account for subdivisions of body
composition such as total body water (TBW) are more expensive, and less broadly used in
clinical and research settings (Das, 2003, 2005). Therefore, it is important to compare
common tools of body composition assessment such as ADP and DXA in a variety of
situations involving obese individuals to further validate this equipment in accurately
estimating body composition.
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Methods
Subjects
Subjects were recruited via email, posted flyers, and word of mouth within the
community. To be included in the study, subjects had to be between the ages of 18 and 45 yr.
Subjects were apparently healthy (i.e., no signs or symptoms of disease) and were non-
smokers. Subjects with a BMI of 18.5-24.9 kg·m-2 were classified as NW. Subjects with a
BMI of 30.0-39.9 kg·m-2 were classified as OB.
Subjects were excluded from the study if their BMI was not within the mentioned
ranges. Subjects were also excluded for taking medication that effected hydration level
(diuretics and/or corticosteroids), if they had a history of smoking, had any lung dysfunction
that could potentially change lung volumes, or if subjects had any type of metal plating
within their body. The project was approved by the local Institutional Review Board (IRB#
18-0355), and all subjects voluntarily provided informed consent prior to participation.
Study Design and Protocol
All testing procedures were completed within a single laboratory visit. Prior to the
study visit, subjects were emailed and asked to bring form fitting clothing. Upon arrival,
subjects completed an informed consent, medical health history questionnaire, and a 24-hour
health history questionnaire. Subsequently, body composition was estimated using ADP with
VTGpred, and VTGmeas, and with the DXA protocol. Test by DXA or methods using ADP
were selected in random order. When ADP was chosen, VTGpred, and VTGmeas were selected
in random order.
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Body Composition with ADP using VTGpred
Steps to calibrate and measure the Bod Pod were consistent with recommendations by
the Bod Pod user’s manual. After the Bod Pod was powered on, the quality control
calibration was used to calibrate the pressure transducers within the chamber. The chamber
was calibrated using a capsule with a known volume (50.122 L). The Bod Pod weight scale
also was calibrated using a standard 20 kg weight. The general population equation was used
to predict VTG in all subjects. Before each subject entered the chamber, they were asked to
remove all jewelry and other SAA other than skin tight gear. A swim cap was placed on each
subject’s head to exclude isothermal air compression of trapped gas within the hair. Body
mass was recorded using the Bod Pod’s scale. The body volume test was initiated once each
subject remained motionless within the Bod Pod during the time of each body volume
measurement. For one successful trial, body volume was measured at least two times. If the
two body volumes were more than 5% different, a third body volume measurement was
initiated. The average value from the two body volumes that were less than 5% different, was
adjusted by a proprietary correction factor and then subsequently used as the volume
component in the calculation of density. If all three body volumes were greater than 5%
different from each other, the entire trial was repeated. Three successful trials were
completed by each subject. Measurements reported from this portion of the visit included
VTGpred, %BFVTGpred, FM from ADP using VTGpred (FMVTGpred) and FFM from ADP using
VTGpred (FFMVTGpred).
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Body composition with ADP using VTGmeas
Calibrations for the Bod Pod using VTGmeas were similar to calibrations for VTGpred,
except before calibration of the pressure transducers, a disposable tube and antimicrobial
filter were added to a port inside the chamber, along with a nose clip that was clipped to the
filter. These pieces of equipment were used during the panting maneuvers; calibrating the
pressure transducers with the equipment inside the chamber corrected for the added volume
said equipment introduces during body volume measurement. Before the subject entered the
Bod Pod, they were thoroughly instructed through the techniques of the test to measure VTG.
Each subject was asked again to remove all jewelry or SAA other than form fitting clothing.
Body mass was recorded using the Bod Pod’s scale. The body volume measurement was
identical to the VTGpred method, except the disposable tube, antimicrobial filter, and nose
clip were in the chamber during each measurement. When the body volume measurements
met the same criteria as for ADP with VTGpred, the VTGmeas was initiated. Each subject was
asked to place their hands on their cheeks and breathe through the internal chamber tube at a
rate guided by the computer monitor while wearing a nose clip. After Vt was established, the
Bod Pod instructed the subject to perform a soft panting maneuver. At the end of an
exhalation, an occlusion occurred during an inspiration of a pant. With the mouth occluded
the pressure measured at the mouth during an inspiratory maneuver is equal to the pressure
within the lungs and can be used to calculate lung volume using Boyle’s law (Dubois 1965).
Following the occluded inspiratory effort, the airway was reopened and the subject came off
of the mouthpiece. The VTGmeas was considered acceptable if the maneuver received a merit
score below 10 and airway pressure below 30 cmH2O (the calculation for merit score was
proprietary) as indicated by the Bod Pod software. If a maneuver was deemed unacceptable,
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the manufacturer recommended the technician ensure the subject pant gentler and make a
tight seal around the mouthpiece. The VTG was measured after each body volume
measurement. The three body composition trials with three reproducible measures of VTG
(error of 5%) were reported. Measurements reported from this portion of the visit included
VTGmeas, %BFVTGmeas, FM from ADP using VTGmeas (FMVTGmeas) and FFM from ADP using
VTGmeas (FFMVTGmeas).
Body Composition using DXA
A standard whole body scan protocol was used to measure body composition via
DXA. To calibrate the DXA machine, a phantom spine with a known (i.e., standard) density
was positioned between two laser cross hairs and the attenuation of X-ray light through the
phantom spine was measured. The calibration passed if measures of density were similar to
the actual density of the reference phantom.
Before testing could commence, the subject’s information, including age, height, and
weight were entered into the system software. Subjects were asked to lay in the supine
position on the scanning table. An attempt to straighten/align the hips prior to the scan was
made by the researcher by instructing subjects to relax their waist while the researcher gently
pulled at the subject’s ankles. Subjects were then asked to sit straight up, take a big breath in,
hold their chin to their chest, and lay back down. This was to ensure that subjects’ spines
were positioned properly for body composition analysis. After the subject was properly
positioned, they were told to point their toes toward each other, then a harness fastened them
in that fixed position. This was done so the full dimensions of the feet could be scanned.
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Then the two minute scan was initiated. Measurements reported from this portion of the visit
included %BFDXA, percent of trunk fat from DXA, FM from DXA, and FFM from DXA.
Data Analyses
Independent t-test were used to test for group differences in age, weight, and height.
A 2 x 2 mixed-design analysis of variance was used to examine the effects of group and
method on measurements of VTG. A 2 x 3 mixed-design analysis of variance was used to
examine the effects of group and method on measurements of %BF. Sphericity was tested
using Mauchly’s test. When the assumption of sphericity was violated, a Geisser-Greenhouse
correction factor was applied. Eta-squared (η2) was used to quantify the effect size of the
variance between measures.  Pearson correlation coefficients (r) were used to assess the
relationship between measured variables. Significance was set at α = 0.05. Data were
reported as mean ± standard deviation (SD).
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Results
4.1 Subject Characteristics
A total of 38 subjects volunteered to participate in the study. Subjects did not qualify
due to having a BMI outside of the qualifying range. Twenty-four (N=24) subjects qualified
for the study and completed all study procedures. All subjects were non-smokers, were
apparently healthy, and were deemed fit to participate in the study based on a brief medical
history, and 24-hour health history questionnaire. Of the 24 subjects who participated in the
study 15 were classified as normal weight (four males) and nine were classified as obese
(nine males). Anthropometric data are provided in Table 1.
Table 1.
Subject Characteristics
Age (yr) Wt (kg) Ht (cm) BMI (kg•m-2)
NW (n=15)
25 ± 7 62.4 ± 6.9 167.4 ± 5.0 22.2 ± 1.7
NW Range 18 - 41 52.2 - 71.8 161.8 - 175.0 18.6 - 24.9
OB (n=9) 24 ± 7 103.5 ± 12.7* 179.4 ± 10.7* 32.1 ± 1.9*
OB Range 21 - 27 91.3 – 128.7 161.1 – 197.5 30.3 - 35.9
Values are mean ± SD. NW, normal weight; OB, obese; Wt, weight; Ht, height; BMI, body
mass index. * Significantly different compared with NW (p < 0.01).
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Measured vs Predicted Thoracic Gas Volumes
Mean values for VTGpred and VTGmeas, along with the mean differences between the
two measurements, are provided in Table 2. There was no group by method interaction
(F1,22 = 3.017, p = 0.096, η2 = 0.11). Additionally, there was no main effect of method
(F1,22 = 2.330, p = 0.141, η2 = 0.09) or main effect for group (F1,22 = 3.685, p = 0.068, η2 =
0.14). The differences between VTGpred and VTGmeas were not significantly related with BMI
(r = 0.33, p = 0.11). However, the differences between VTGpred and VTGmeas were
significantly related with trunk fat percentage (r = 0.47, p = 0.02).
Figure 4 depicts the individual differences between VTGpred and VTGmeas (i.e.,
residuals) plotted against the corresponding VTGpred for all subjects. In the NW group there
were approximately equal numbers of positive and negative residuals. However, in the OB
group there tended to be more positive than negative residuals. The differences between
VTGpred and VTGmeas were not significantly related to VTGpred (r = −0.02, p = 0.945).
Table 2
Predicted and measured VTG
VTGpred(L) VTGmeas(L) Mean ∆(L)
NW (n=15) 3.326 ± 0.232 3.353 ± 0.755 -0.027 ± 0.629
OB (n=9) 4.000 ± 0.515 3.577 ± 0.916 0.420 ± 0.578
Values are mean ± SD. NW, normal weight; OB, obese; VTGpred, predicted thoracic gas
volume; VTGmeas, measured thoracic gas volume; Mean ∆, mean difference of VTGpred and
VTGmeas.
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Figure 4. Thoracic gas volume difference (VTGpred - VTGmeas) against the mean of VTGpred
in normal weight (•) and obese (□) subjects; VTGpred, predicted thoracic gas volume; VTG
residuals; difference between VTGpred, and VTGmeas (r = −0.02, p = 0.945).
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Table 3
Measures of Body Fat using ADP and DXA
%BFVTGpred(%) %BFVTGmeas(%) %BFDXA(%)
NW (n=15) 24.7 ± 6.4 24.5 ± 5.3 26.1 ± 5.1
OB (n=9) 32.9 ± 4.3 32.2 ± 3.9 30.9 ± 3.0
Values are mean ± SD. NW, normal weight; OB, obese; %BFVTGpred, percent body fat from
predicted thoracic gas volume; %BFVTGmeas, percent body fat from measured thoracic gas
volume; %BFDXA, percent body fat from DXA.
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Mean values for %BFVTGpred, %BFVTGmeas, and %BFDXA can be found in Table 3.
There was a significant group by method interaction for the measure of %BF (F2,44 = 10.060,
p = 0.001, η2 = 0.31). Additionally, there was a significant main effect for group in %BF
(F1,22 = 10.944, p = 0.003, η2 = 0.01), but not for method (F2,44 = 0.663, p = 0.479, η2 = 0.33).
Mean values for FMVTGpred, FMVTGmeas, and FMDXA can be found in Table 4. There was a
significant group by method interaction for the measures of FM (F2,44 = 9.944, p < 0.001,
η2 = 0.30). Additionally, there was a significant main effect for group in FM (F1,22 = 78.616,
p < 0.001, η2 = 0.11). Mean values for FFMVTGpred, FFMVTGmeas, and FFMDXA can be found in
Table 5. There were a significant group by method interaction for the measures of FFM
Table 4
Measures of FM using ADP and DXA
FMVTGpred(kg) FMVTGmeas(kg) FMDXA(kg)
NW (n=15) 15.5 ± 4.8 15.4 ± 4.2 16.6 ± 4.3
OB (n=9) 34.0 ± 5.1 33.2 ± 5.2 32.6 ± 5.3
Values are mean ± SD. NW, normal weight; OB, obese; Values are mean ± SD; FMVTGpred,
fat mass from predicted thoracic gas volume; FMVTGmeas, fat mass from measured thoracic
gas volume.
Table 5
Measures of FFM using ADP and DXA
FFMVTGpred(kg) FFMVTGmeas(kg) FFMDXA(kg)
NW (n=15) 46.9 ± 6.1 47.0 ± 5.5 46.7 ± 5.2
OB (n=9) 69.6 ± 10.4 70.3 ± 9.9 56.5 ± 14.6
Values are mean ± SD. NW, normal weight; OB, obese; Values are mean ± SD;
FFMVTGpred, fat free mass from predicted thoracic gas volume; FFMVTGmeas, fat free mass
from measured thoracic gas volume.
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(F2,44 = 20.995, p < 0.001, η2 = 0.36). Additionally, there were significant main effects for
group (F1,22 = 58.936, p < 0.001, η2 = 0.04) and method in FFM measures (F2,44 = 0.998,
p < 0.001, η2 = 0.27). The mean differences of %BFVTGpred, and %BFVTGmeas plotted against
the measure of %BFVTGpred in the NW and OB groups are shown in Figure 5. At lower
%BFVTGpred, there were large negative residuals, but the residuals were positive at higher
%BFVTGpred. As a result, the differences between %BFVTGpred and %BFVTGmeas were
significantly related to %BFVTGpred (r = 0.60, p = 0.002). In the OB group, the majority of the
residuals were positive.
Figure 5. Percent body fat difference (%BFVTGpred - %BFVTGmeas) across %BFVTGpred in normal
weight (•) and obese (□) subjects; %BFVTGpred, percent body fat from predicted thoracic gas.
volume; %BFVTGmeas, percent body fat from measured thoracic gas volume; %BF Residuals,
the difference of %BFVTGpred, and %BFVTGmeas (r = 0.60, p = 0.002).
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The amount of error of estimating %BFVTGpred is shown in Figure 6. The differences
between VTGpred and VTGmeas were significantly related with the differences between
%BFVTGpred and %BFVTGmeas (r = 0.92, p < 0.001). In the NW group, there was an even
distribution of individuals who had their VTG either under or over predicted compared with
VTGmeas. A large cluster of NW subjects had no large differences both in the estimation of
VTG and estimation of %BF compared with respective measured parameters. The majority
of the obese subjects had both their VTG and %BF overestimated.
Figure 6. Difference in %BF (%BFVTGpred - %BFVTGmeas) as a function of difference in VTG
(VTGpred - VTGmeas) for normal weight (•) and obese (□) subjects; VTG residuals; difference
between VTGpred, and VTGmeas; %BF Residuals, the difference of %BFVTGpred, and
%BFVTGmeas (r = 0.92, p < 0.001).
The mean differences of measured %BFDXA and %BFVTGpred are plotted against
%BFDXA in NW and OB subjects in Figure 7. The differences between %BFVTGpred and
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%BFDXA were significantly related to %BFDXA (r = 0.92, p < 0.001). In the NW group, there
were more positive residuals; in the OB group, there were more negative residuals. Figure 8
depicts the mean differences of measured %BFDXA and %BFVTGpred plotted against %BFDXA
in NW, and OB groups. In the NW group there were more positive residuals; in the OB
group, there were more negative residuals. The differences between %BFVTGmeas and
%BFDXA were significantly related to %BFDXA (r = 0.95, p < 0.001).
Figure 7. Percent body fat difference (%BFDXA - %BFVTGpred) against the mean of %BFDXA in
normal weight (•) and obese (□) subjects; %BFVTGpred, percent body fat from predicted
thoracic gas volume; %BFDXA, percent body fat from the DXA (r = 0.92, p < 0.001).
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Figure 8. Percent body fat difference (%BFDXA - %BFVTGmeas) against the mean of %BF DXA
in normal weight (•) and obese (□) subjects; %BFVTGmeas, percent body fat from measured
thoracic gas volume; %BFDXA, percent body fat from the DXA (r = 0.95, p < 0.001).
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Discussion
Main Findings
The differences between VTGpred and VTGmeas were not significantly different within
the OB and NW subjects, but the moderate effect size (η2) indicates differences may be
observed with a larger sample size. Differences between VTGpred and VTGmeas were not
associated with BMI but were significantly related to trunk fat percentage. OB played a
significant role into the error of %BF estimations. Within the OB group, %BF was reduced
using DXA than with either ADP method. In contrast, %BF was greater using DXA than
with either ADP method in the NW group. The differences between VTGpred and VTGmeas
were strongly related to differences between %BFVTGpred and %BFVTGmeas. Consequently,
because the OB group showed a trend of having their VTG overestimated (compared to when
measured), OB individuals also had overestimated values of %BF. Although this study is
underpowered, there appears to be an impact of body composition on estimates of %BF due
to altered operational lung volumes; this calls for more attention to be focused on the method
of measurement used in an obese population.
Subject Characteristics
All of the NW and OB subjects were apparently healthy, non-smokers. Each group
displayed body composition (%BF) typical of their BMI classification. The two groups differed
greatly by sex, with 11 females in the NW group and no females in the OB group. Males tend
to have more fat free mass, and females tend to have more fat mass (Wellens, 1994). While
BMI is not directly related to %BF, the %BF of the NW group using either ADP or DXA was
consistent with %BF that are typically observed in relation to BMI with both males and females
in a NW population; males and females with a BMI of less than 25 kg∙m-2 usually have a %BF
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that was below 25% and 35% respectively (Hanes, 2014; Lorenzo, 2003). This evidence is
consistent with what this study found, with methods using ADP or DXA mean %BF ranged
from 24% – 27%. Despite the OB group being entirely males, their higher BMI was not due to
just a significant height difference, but also a larger %BF, males who were classified as obese
had %BF greater than 30% using ADP or DXA. This finding is consistent with a typical %BF
in this population (%BF 30% or greater) (Lorenzo, 2003). Regardless of sex differences,
decreased respiratory compliance and operational lung volumes are typical in obese adults
(Harris, 2005; Norman, 1960). Thus, while the current study only observed obese males, obese
females would be expected to have differences in VTG at rest due to decreases in FRC that are
associated with a larger BMI similar to males.
VTG Differences
Being obese did not significantly over predict VTG compared to normal weight
adults. There was also no relationship between BMI and difference between VTGpred and
VTGmeas; however, there was a significant positive relationship between trunk fat percentage
and differences between VTGpred and VTGmeas. BMI is known to be associated with
decreases in operational lung volumes, primarily because of the increased adiposity around
the chest wall and abdominal cavity (Koenig, 2001b; Littleton, 2012; Sampson, 1983).
Although there were no significant differences observed between VTGpred and VTGmeas in the
OB adults, the current effect size may indicate that a larger sample size would result in
significant differences observed between the methods in the OB but not the NW subjects.
Yet, the lack of statistical significance could either be because the measured VTG was not
related to resting FRC, or the excess fat of the OB group was not distributed in an area that
could impede total respiratory compliance. The relationship that we found with trunk fat
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percentage and VTG differences indicate that the small differences that we did see were in
part, due to the location of fat. Based on the relationships described above regarding %BF
and VTG, greater differences in VTG due to trunk fat percentage could result in further error
on %BF estimations by ADP.
VTG is not FRC
The Bod Pod predicts lung volumes based on the estimation of the midpoint of tidal
volume, plus the predicted FRC (Aitkens, 1995). Although VTG and FRC are closely related,
they are not the same. VTG refers to the amount of volume in the lungs at the time of
measurement. During a measurement, a subject may exhale to FRC, but at the moment they
inhale, lung volumes will no longer be at FRC. To take into consideration the net amount air
in the lungs at any given point in the test, the midpoint best represents the average amount of
air that is in the lungs. As such, predicted VTG is expected to be slightly larger than FRC.
Minor alterations in breathing patterns or positioning may alter the volume amount
within the lungs at the time of measurement. In terms of the actual measurement of lung
volumes, it is difficult to get true measures of tidal volume (Vt) using standard techniques.
Typical methods to measure lung volumes usually involve a pneumatic device connected to
the subject, along with a firmly fastened nose clip. These methods are often uncomfortable
and could result in alterations to normal, resting breathing patterns. A study was done
observing the differences in breathing patterns with the use of pneumatic device and nose
clip, versus the less invasive magnetometer in subjects while resting in bed (Figure 9). In
nearly all cases the addition of the respiratory apparatus caused a subsequent increase in Vt,
(124 ± 80 ml) and a decrease in breathing frequency (Gilbert, 1972). In other words, when a
nose clip and spirometric measuring device were added, the very values that were intended
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on being measured were altered. Therefore it is important to note that due to measurement of
VTG within the Bod Pod, lung volumes may have been altered.
Figure 9. Changes while lying supine at rest to tidal volumes from magnetometer to
respiratory apparatus; breathing frequency, and ventilation. M. magnetomoter; RA.
respiratory apparatus (Gilbert, 1972).
The under-prediction of NW VTG may be, in part, due to these altered breathing
patterns to compensate for changes not usually experienced during uninterrupted breathing.
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Subjects may breathe at higher lung volumes compared with what is predicted according to
age and height because they are breathing atypically.
Mean differences in lung volumes observed in the OB group, in contrast to the
normal weight group, averaged 816 ml less than what was predicted. Due to the increased
adiposity around the thoracic cavity usually associated with those with higher BMI, lung
volumes in this population are decreased (Jones, 2006), particularly in those with a BMI ≥ 30
kg∙m2 (Figure 10).
Figure 10. Effects of BMI on functional residual capacity (FRC); NS, not significant (Jones,
2006).
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Although VTG and FRC are different measures, if FRC decreases, VTG will also
decrease. Measured VTG in the obese group was approximately 75% of predicted, while in
the two groups combined, VTG was measured to be 86 ± 18% of predicted. This finding is
consistent with other studies examining decreases in lung volumes attributed to obesity.
While significant differences between groups were not found, the OB group had lung
volumes over-predicted by the Bod Pod, as a result, had an over-estimated %BF. While this
study is under-powered, these trends have the potential to be significant with a larger sample
of obese adults. If in fact these trends remain true, this would indicate that those with higher
BMI will have their VTG, and perhaps the resulting %BF, over-estimated when not
measuring VTG.
%BF Estimates
There were no significant differences in measures of %BF by ADP. However, BMI
and/or body composition did affect %BFDXA differently than in normal weight adults.
Specifically, %BFDXA in OB adults was lower than ADP by approximately 2%. In contrast,
%BFDXA in NW adults was greater than ADP by approximately 2%. A strong correlation
between VTG differences (VTGpred − VTGmeas) and %BF differences
(%BFVTGpred − %BFVTGmeas) indicated that errors in VTG will result in errors in %BF. Low
%BFVTGpred in the NW group resulted in larger differences in %BFVTGpred and %BFVTGmeas.
Upon further analysis 8 normal weight individuals displayed measured lung volumes that
averaged to be 113 % of the predicted VTG. These under estimated predictions of VTG
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could have resulted in underestimation of %BF in the NW group. For large amounts of
%BFVTGpred, typical in obesity differences were also greater.
Being OB had a significant effect on the values of estimated %BF across the three
methods (VTGpred, VTGmeas, and DXA). A significant main effect by group indicates that OB
adults, in fact, had more %BF then their NW counterparts. Ultimately, being OB was not
only related with greater %BF but larger differences between methods for estimating %BF.
When the differences of VTGpred and VTGmeas were compared to the differences of
%BFVTGpred, and %BFVTGpred, there was a strong positive correlation (r = 0.92, p < 0.001),
showing that the error in predicting VTG will affect the subsequent estimate of %BF from
ADP. A large cluster of NW subjects did not have large differences in VTGpred and VTGmeas,
and therefore, the %BF estimates often agreed between the two methods. The large majority
of OB subjects displayed an over estimated VTG, which resulted in an overestimation of
%BF.
When %BFDXA was compared to VTGpred and VTGmeas (Figure 7, Figure 8), the DXA
estimation of %BF was lower in the OB group, but tended to estimate higher %BF than
VTGpred and VTGmeas in the NW group. DXA has been shown to result in lower %BF
estimates compared to ADP estimates of %BF in obese individuals (Sampson, 1983). For
example, in 57 severely obese women, DXA estimated %BF to be 2.4% lower than ADP
(Bedogni, 2013). In contrast, in normal weight adults, measures of %BFDXA have been found
to be larger than ADP by 3% (Levenhagen, 1999). In females the difference in estimates
from DXA and ADP appeared to be more substantial than in males. The results of our study
are consistent with other previous findings, however there were some discrepancies. For
example, a study including 109 participants, who divided groups by BMI, reported %BF
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from DXA in their NW and OB group to be approximately 2.5% higher than %BFVTGpred.
Yet, the severely OB group values for %BFDXA was 2.7% less than %BFVTGpred (Hanes,
2014). A study with 15 normal weight subjects, and 19 overweight/obese subjects reported
%BFVTGpred to be 2.43% greater than %BFDXA and 1.46% less than %BFDXA in the
overweight/obese group. Some of the differences observed in OB adults may have been
mitigated by grouping together overweight and obese adults.
Error in %BF Estimates
Measuring true body composition is not yet possible in living humans. When the
ADP and DXA devices estimate %BF, there are assumptions that are made of the
composition of the body. For example, with ADP and DXA, a constant fat free mass
hydration status is assumed (Aitkens, 1995; Pietrobelli, 1996; Siri, 1961). Hydration status
that may deviate from what is normal has the potential to increase the error in %BF
estimates.
DXA uses a three-compartment model to estimate body composition. Theoretically,
by taking more compartments of the body into consideration, resultant measures of body fat
should be more accurate. An added benefit of DXA, in contrast to ADP, is that the
calculation of %BF is independent from the amount of gas in the lungs at any given time of
measurement. Although it is impossible to get a direct measure of %BF in a living human,
results from DXA should provide a closer estimation to the true body composition than the
two-compartment model used in ADP.
Errors in calculated %BF by DXA arise from factors that will affect the attenuation of
the different energy level X-ray beams that pass through the body. Some of these factors
include tissue thickness, hydration status, and body fat distribution all of which are altered
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with obesity (Hanes, 2014; Jensen, 2019). Past studies have shown strong agreement in NW
populations and measures of %BF from DXA and ADP (Ballard, 2004; Flakoll, 2004).
Observed differences in %BF in DXA compared with ADP could be due to the quantity and
location of fat distribution in the NW versus OB population. Body composition can be
greatly affected by confounding factors present in children and youth (≤18 years) along with
older adults (≥ 40 years). Within these age groups, there are several body composition
changes that could skew resultant values of FM and FFM independent of FRC, methodology
used in determining %BF in OB individuals compared to their NW counterparts. In FFM of
children and youth, there are changes in water and mineral content that tend to violate the
soft tissue density assumptions for this population (Boileau, 1985; Lohman, 1984; Siri,
1961). With older groups, there are changes in bone mineralization and hydration of the fat
free mass due to aging and factors such as menopause and disease states. Methods based on
the two-compartment model to estimate FM and FFM may also be limited by these
deleterious changes (Baumgartner, 1991; Clasey, 1999; Fields, 2004; Heymsfield, 1989;
Toth, 2000). Similarly in obese populations, hydration status and total body water (TBW)
deviate from what is appraised as normal, and should be considered when analyzing body
composition in obese adults.
Future studies examining body composition in normal weight and obese individuals
should consider a more detailed classification of fatness that considers the distribution of fat
throughout the body. For example, values of waist and hip circumference could prove helpful
in showing supporting evidence of %BF changes concurrent with different methods of body
composition measurement. Further, because hydration status of fat and muscle cells can play
45
a key role in changing the assumptions that uniform density suggest, measuring hydration
status of the body will help refine estimations of body composition.
Conclusion
The differences observed in %BF estimates between VTGpred, VTGmeas, and DXA in
this study indicate that methods of measuring body composition via ADP cannot be used
interchangeably with DXA. Additionally, individuals monitoring body composition should
be consistent with the method and device that they are utilizing. With weight loss, differences
between VTGpred and VTGmeas will be mitigated, and subsequent estimates of %BF with ADP
will be more similar. With changes in weight, DXA, in contrast to ADP, will give the most
similar estimates of %BF compared with a four-compartment model method. It is important
to consider the effect that obesity may have on body composition measurements using ADP,
and to ensure that appropriate methods are being used to test this population.
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Appendix A
Raw Data
Screen Captures of Raw Data from Subject Information:
LN STUDY ID GRP STATUS Ethnicity AGE DOB SEX CODE HT (cm) WT (kg) WT:HT BMI HxDOE snore-subjective
snore-
objective Hx Asth
1 VTG 014 OB Completed Hisp 22 8/17/1996 M Mean 177.0 94.9 0.536 30.3 No No No None
2 VTG 015 OB Completed Not Hisp 21 . M Mean 172.0 92.7 0.539 31.3 No Yes Yes None
3 VTG 016 NW Completed Not Hisp 34 2/19/1985 F Mean 169.5 53.5 0.316 18.6 No No No None
6 VTG 019 OB Completed Not Hisp 23 9/17/1995 M Mean 161.1 93.1 0.578 35.9 No No No None
7 VTG 020 NW Completed Not Hisp 23 4/5/1996 F Mean 171.2 66.3 0.387 22.6 No No No None
8 VTG 021 NW Completed Hisp 21 4/12/1998 M Mean 175.0 70.0 0.400 22.9 No No No None
9 VTG 022 NW Completed Not Hisp 32 12/5/1986 M Mean 163.5 59.0 0.361 22.1 No No No None
10 VTG 023 NW Completed Not Hisp 41 4/6/1978 F Mean 167.5 68.8 0.411 24.5 No No No None
11 VTG 024 OB Completed Not Hisp 23 8/27/1995 M Mean 173.4 91.9 0.530 30.6 No Yes Yes None
12 VTG 025 OB Completed Not Hisp 24 6/11/1995 M Mean 182.9 111.1 0.607 33.2 No Yes Yes None
14 VTG 027 NW Completed Not Hisp 20 12/7/1998 F Mean 172.5 71.8 0.416 24.1 No Yes Yes None
15 VTG 028 NW Completed Hisp 21 12/26/1997 F Mean 166.5 56.6 0.340 20.4 No . . .
17 VTG 030 OB Completed Not Hisp 25 3/25/1994 M Mean 191.5 115.0 0.600 31.4 No No No None
18 VTG 031 NW Completed Not Hisp 33 11/16/1985 F Mean 167.6 70.0 0.418 24.9 . . . .
19 VTG 032 NW Completed Not Hisp 18 12/17/2000 F Mean 166.5 64.7 0.389 23.3 No No No None
20 VTG 033 NW Completed Not Hisp 18 3/19/2001 F Mean 161.8 53.5 0.331 20.4 No No No None
21 VTG 034 NW Completed Not Hisp 19 4/17/2000 F Mean 164.0 55.0 0.335 20.4 No No No None
22 VTG 035 OB Completed Hisp 27 2/7/1991 M Mean 181.1 98.3 0.543 30.0 No Yes Yes None
23 VTG 036 NW Completed Not Hisp 22 3/3/1997 F Mean 155.0 52.2 0.337 21.7 No No No None
24 VTG 037 NW Completed Not Hisp 22 3/20/1996 M Mean 171.0 65.0 0.380 22.2 No Yes Yes None
25 VTG 038 NW Completed Not Hisp 23 4/14/1996 M Mean 171.5 68.1 0.397 23.2 No No No None
26 VTG 039 NW Completed Not Hisp 21 4/24/2019 F Mean 168.5 60.9 0.361 21.4 No No No None
28 VTG 041 OB Completed Not Hisp 22 3/17/1997 M Mean 178.5 106.1 0.594 33.3 No No No None
29 VTG 042 OB Completed Not Hisp 25 6/12/1994 M Mean 197.5 128.7 0.652 33.0 . Yes Yes None
Asthma
Info
Smoke
HX Pks/day Years Sm Pks/yr Ex Type Ex
ExFreq
(per/wk)
ExDuratio
n (min) Meds Processing
N/A No 0 0 0 No Sedentary N/A N/A Atarax; Singulair JO
N/A No 0 0 0 Yes Cycling 1 30.0 None JO
N/A No 0 0 0 Yes Running 2 30.0 None JO
N/A No 0 0 0 Yes Walking 4 30.0 Xyzal JO
N/A No 0 0 0 Yes Running 3 20.0 None JO
N/A No 0 0 0 Yes N/A N/A N/A None JO
N/A No 0 0 0 Yes Jump Rope 5 15.0 None JO
N/A No 0 0 0 . Multiple 7 90.0 Synthroid; Yaz; Zyrtec JO
N/A No 0 0 0 Yes Running 2 20.0 None JO
N/A No 0 0 0 Yes Hiking 2 120.0 None JO
N/A No No 0 0 Yes Cycling 3.5 20.0 Concerta; Zyrtec JO
. . . . . . . . . . JO
N/A No 0 0 0 Yes Weightlifting N/A N/A None JO
. . . . . . . . . . JO
N/A No 0 0 0 Yes Soccer 5 90.0 None JO
N/A No 0 0 0 Yes Soccer 5 90.0 Tri Previfem JO
N/A No 0 0 0 Yes Soccer 7 60.0 Vienva JO
N/A No 0 0 0 Yes Cycling 3 30.0 None JO
N/A No 0 0 0 Yes Dance 3 30.0 None JO
N/A No 0 0 0 Yes Running 3 180.0 None JO
N/A No 0 0 0 Yes Running 3 30.0 None JO
N/A No 0 0 0 Yes Cycling 3 30.0 Birth Control JO
N/A No 0 0 0 No N/A N/A N/A Ibuprofen JO
N/A No 0 0 0 Yes N/A N/A N/A Buspirone; Lisinopril; Trazodone JO
LN STUDY ID GRP STATUS Ethnicity AGE DOB SEX CODE HT (cm) WT (kg) WT:HT BMI HxDOE snore-subjective
snore-
objective Hx Asth
1 VTG 014 OB Completed Hisp 22 8/17/1996 M Mean 177.0 94.9 0.536 30.3 No No No None
2 VTG 015 OB Completed Not Hisp 21 . M Mean 172.0 92.7 0.539 31.3 No Yes Yes None
3 VTG 016 NW Completed Not Hisp 34 2/19/1985 F Mean 169.5 53.5 0.316 18.6 No No No None
6 VTG 019 OB Completed Not Hisp 23 9/17/1995 M Mean 161.1 93.1 0.578 35.9 No No No None
7 VTG 020 NW Completed Not Hisp 23 4/5/1996 F Mean 171.2 66.3 0.387 22.6 No No No None
8 VTG 021 NW Completed Hisp 21 4/12/1998 M Mean 175.0 70.0 0.400 22.9 No No No None
9 VTG 022 NW Completed Not Hisp 32 12/5/1986 M Mean 163.5 59.0 0.361 22.1 No No No None
10 VTG 023 NW Completed Not Hisp 41 4/6/1978 F Mean 167.5 68.8 0.411 24.5 No No No None
11 VTG 024 OB Completed Not Hisp 23 8/27/1995 M Mean 173.4 91.9 0.530 30.6 No Yes Yes None
12 VTG 025 OB Completed Not Hisp 24 6/11/1995 M Mean 182.9 111.1 0.607 33.2 No Yes Yes None
14 VTG 027 NW Completed Not Hisp 20 12/7/1998 F Mean 172.5 71.8 0.416 24.1 No Yes Yes None
15 VTG 028 NW Completed Hisp 21 12/26/1997 F Mean 166.5 56 6 0.340 20.4 No . . .
17 VTG 030 OB Completed Not Hisp 25 3/25/1994 M Mean 191.5 115.0 0.600 31.4 No No No None
18 VTG 031 NW Completed Not Hisp 33 11/16/1985 F Mean 167.6 70 0 0.418 24.9 . . . .
19 VTG 032 NW Completed Not Hisp 18 12/17/2000 F Mean 166.5 64.7 0.389 23.3 No No No None
20 VTG 033 NW Completed Not Hisp 18 3/19/2001 F Mean 161.8 53.5 0.331 20.4 No No No None
21 VTG 034 NW Completed Not Hisp 19 4/17/2000 F Mean 164.0 55.0 0.335 20.4 No No No None
22 VTG 035 OB Completed Hisp 27 2/7/1991 M Mean 181.1 98.3 0.543 30.0 No Yes Yes None
23 VTG 036 NW Completed Not Hisp 22 3/3/1997 F Mean 155.0 52.2 0.337 21.7 No No No None
24 VTG 037 NW Completed Not Hisp 22 3/20/1996 M Mean 171.0 65.0 0.380 22.2 No Yes Yes None
25 VTG 038 NW Completed Not Hisp 23 4/14/1996 M Mean 171.5 68.1 0.397 23.2 No No No None
26 VTG 039 NW Completed Not Hisp 21 4/24/2019 F Mean 168.5 60.9 0.361 21.4 No No No None
28 VTG 041 OB Completed Not Hisp 22 3/17/1997 M Mean 178.5 106.1 0.594 33.3 No No No None
29 VTG 042 OB Completed Not Hisp 25 6/12/1994 M Mean 197.5 128.7 0.652 33.0 . Yes Yes None
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Screen Captures of Raw Data from VTGpred:
ID GRP Code TRIAL PB Temp RH Mass (kg) VTGp VTG
ΔVTG
(pred-
meas)
VTGpp
014 OB PRED 1 . . . 94.9 3.869 3.869 0.000 100.0
014 OB PRED 2 . . . 94.9 3.869 3.869 0.000 100.0
014 OB PRED 3 . . . . 3.869 3.869 0.000 100.0
014 OB PRED Mean . . . 94.86 3.869 3.869 0.000 100.0
015 OB PRED 1 682.49 22.0 52.0 92.7 3.624 3.624 0.000 100.0
015 OB PRED 2 682.49 22.0 52.0 92.7 3.624 3.624 0.000 100.0
015 OB PRED 3 682.49 22.0 52.0 . 3.624 3.624 . .
015 OB PRED Mean 682.49 22.0 52.0 92.71 3.624 3.624 0.000 100.0
016 NW PRED 1 678.00 21.0 40.0 53.5 3.376 3.376 0.000 100.0
016 NW PRED 2 678.00 21.0 40.0 53.5 3.376 3.376 0.000 100.0
016 NW PRED 3 678.00 21.0 40.0 53.5 3.376 3.376 0.000 100.0
016 NW PRED Mean 678.00 21.0 40.0 53.47 3.376 3.376 0.000 100.0
019 OB PRED 1 681.00 22.0 51.0 93.3 3.127 3.127 0.000 100.0
019 OB PRED 2 681.00 22.0 51.0 93.1 3.127 3.127 0.000 100.0
019 OB PRED 3 681.00 22.0 51.0 93.1 3.127 3.127 0.000 100.0
019 OB PRED Mean 681.00 22.0 51.0 93.17 3.127 3.127 0.000 100.0
020 NW PRED 1 681.70 22.0 47.0 66.3 3.403 3.403 0.000 100.0
020 NW PRED 2 681.70 22.0 47.0 66.3 3.403 3.403 0.000 100.0
020 NW PRED 3 681.70 22.0 47.0 66.3 3.403 3.403 0.000 100.0
020 NW PRED Mean 681.70 22.0 47.0 66.35 3.403 3.403 0.000 100.0
021 NW PRED 1 681.00 22.0 51.0 70.0 3.760 3.760 0.000 100.0
021 NW PRED 2 681.00 22.0 51.0 70.0 3.760 3.760 0.000 100.0
021 NW PRED 3 681.00 22.0 51.0 70.0 3.760 3.760 0.000 100.0
021 NW PRED Mean 681.00 22.0 51.0 70.03 3.760 3.760 0.000 100.0
022 NW PRED 1 680.20 22.0 53.0 59.1 3.320 3.320 0.000 100.0
022 NW PRED 2 680.20 22.0 53.0 59.1 3.320 3.320 0.000 100.0
022 NW PRED 3 680.20 22.0 53.0 59.1 3.320 3.320 0.000 100.0
022 NW PRED Mean 680.20 22.0 53.0 59.12 3.320 3.320 0.000 100.0
023 NW PRED 1 678.18 22.0 45.0 68.8 3.326 3.326 0.000 100.0
023 NW PRED 2 678.18 22.0 45.0 68.8 3.326 3.326 0.000 100.0
023 NW PRED 3 678.18 22.0 45.0 68.8 3.326 3.326 0.000 100.0
023 NW PRED Mean 678.18 22.0 45.0 68.82 3.326 3.326 0.000 100.0
024 OB PRED 1 682.40 21.0 54.0 202.7 3.709 3.709 0.000 100.0
024 OB PRED 2 682.40 21.0 54.0 202.7 3.709 3.709 0.000 100.0
024 OB PRED 3 682.40 21.0 54.0 202.7 3.709 3.709 0.000 100.0
024 OB PRED Mean 682.40 21.0 54.0 202.70 3.709 3.709 0.000 100.0
025 OB PRED 1 682.50 22.0 54.0 111.1 4.159 4.159 0.000 100.0
025 OB PRED 2 682.50 22.0 54.0 111.1 4.159 4.159 0.000 100.0
025 OB PRED 3 682.50 22.0 54.0 111.1 4.159 4.159 0.000 100.0
025 OB PRED Mean 682.50 22.0 54.0 111.07 4.159 4.159 0.000 100.0
027 NW PRED 1 684.00 22.0 51.0 71.8 3.442 3.442 0.000 100.0
027 NW PRED 2 684.00 22.0 51.0 71.8 3.442 3.442 0.000 100.0
027 NW PRED 3 684.00 22.0 51.0 71.8 3.442 3.442 0.000 100.0
027 NW PRED Mean 684.00 22.0 51.0 71.82 3.442 3.442 0.000 100.0
028 NW PRED 1 . . . 56.6 3.229 3.229 0.000 100.0
028 NW PRED 2 . . . 56.7 3.229 3.229 0.000 100.0
028 NW PRED 3 . . . 56.7 3.229 3.229 0.000 100.0
028 NW PRED Mean #DIV/0! #DIV/0! #DIV/0! 56.67 3.229 3.229 0.000 100.0
030 OB PRED 1 682.50 21.0 34.0 114.9 4.577 4.577 0.000 100.0
030 OB PRED 2 682.50 21.0 34.0 115.0 4.577 4.577 0.000 100.0
030 OB PRED 3 682.50 21.0 34.0 115.0 4.577 4.577 0.000 100.0
030 OB PRED Mean 682.50 21.0 34.0 114.97 4.577 4.577 0.000 100.0
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ID GRP Code TRIAL PB Temp RH Mass (kg) VTGp VTG
ΔVTG
(pred-
meas)
VTGpp
014 OB PRED 1 . . . 94.9 3.869 3.869 0.000 100.0
014 OB PRED 2 . . . 94.9 3.869 3.869 0.000 100.0
014 OB PRED 3 . . . . 3.869 3.869 0.000 100.0
014 OB PRED Mean . . . 94.86 3.869 3.869 0.000 100.0
015 OB PRED 1 682.49 22.0 52.0 92.7 3.624 3.624 0.000 100.0
015 OB PRED 2 682.49 22.0 52.0 92.7 3.624 3.624 0.000 100.0
015 OB PRED 3 682.49 22.0 52.0 . 3.624 3.624 . .
015 OB PRED Mean 682.49 22.0 52.0 92.71 3.624 3.624 0.000 100.0
016 NW PRED 1 678.00 21.0 40.0 53.5 3.376 3.376 0.000 100.0
016 NW PRED 2 678.00 21.0 40.0 53.5 3.376 3.376 0.000 100.0
016 NW PRED 3 678.00 21.0 40.0 53.5 3.376 3.376 0.000 100.0
016 NW PRED Mean 678.00 21.0 40.0 53.47 3.376 3.376 0.000 100.0
019 OB PRED 1 681.00 22.0 51.0 93.3 3.127 3.127 0.000 100.0
019 OB PRED 2 681.00 22.0 51.0 93.1 3.127 3.127 0.000 100.0
019 OB PRED 3 681.00 22.0 51.0 93.1 3.127 3.127 0.000 100.0
019 OB PRED Mean 681.00 22.0 51.0 93.17 3.127 3.127 0.000 100.0
020 NW PRED 1 681.70 22.0 47.0 66.3 3.403 3.403 0.000 100.0
020 NW PRED 2 681.70 22.0 47.0 66.3 3.403 3.403 0.000 100.0
020 NW PRED 3 681.70 22.0 47.0 66.3 3.403 3.403 0.000 100.0
020 NW PRED Mean 681.70 22.0 47.0 66.35 3.403 3.403 0.000 100.0
021 NW PRED 1 681.00 22.0 51.0 70.0 3.760 3.760 0.000 100.0
021 NW PRED 2 681.00 22.0 51.0 70.0 3.760 3.760 0.000 100.0
021 NW PRED 3 681.00 22.0 51.0 70.0 3.760 3.760 0.000 100.0
021 NW PRED Mean 681.00 22.0 51.0 70.03 3.760 3.760 0.000 100.0
022 NW PRED 1 680.20 22.0 53.0 59.1 3.320 3.320 0.000 100.0
022 NW PRED 2 680.20 22.0 53.0 59.1 3.320 3.320 0.000 100.0
022 NW PRED 3 680.20 22.0 53.0 59.1 3.320 3.320 0.000 100.0
022 NW PRED Mean 680.20 22.0 53.0 59.12 3.320 3.320 0.000 100.0
023 NW PRED 1 678.18 22.0 45.0 68.8 3.326 3.326 0.000 100.0
023 NW PRED 2 678.18 22.0 45.0 68.8 3.326 3.326 0.000 100.0
023 NW PRED 3 678.18 22.0 45.0 68.8 3.326 3.326 0.000 100.0
023 NW PRED Mean 678.18 22.0 45.0 68.82 3.326 3.326 0.000 100.0
024 OB PRED 1 682.40 21.0 54.0 202.7 3.709 3.709 0.000 100.0
024 OB PRED 2 682.40 21.0 54.0 202.7 3.709 3.709 0.000 100.0
024 OB PRED 3 682.40 21.0 54.0 202.7 3.709 3.709 0.000 100.0
024 OB PRED Mean 682.40 21.0 54.0 202.70 3.709 3.709 0.000 100.0
025 OB PRED 1 682.50 22.0 54.0 111.1 4.159 4.159 0.000 100.0
025 OB PRED 2 682.50 22.0 54.0 111.1 4.159 4.159 0.000 100.0
025 OB PRED 3 682.50 22.0 54.0 111.1 4.159 4.159 0.000 100.0
025 OB PRED Mean 682.50 22.0 54.0 111.07 4.159 4.159 0.000 100.0
027 NW PRED 1 684.00 22.0 51.0 71.8 3.442 3.442 0.000 100.0
027 NW PRED 2 684.00 22.0 51.0 71.8 3.442 3.442 0.000 100.0
027 NW PRED 3 684.00 22.0 51.0 71.8 3.442 3.442 0.000 100.0
027 NW PRED Mean 684.00 22.0 51.0 71.82 3.442 3.442 0.000 100.0
028 NW PRED 1 . . . 56.6 3.229 3.229 0.000 100.0
028 NW PRED 2 . . . 56.7 3.229 3.229 0.000 100.0
028 NW PRED 3 . . . 56.7 3.229 3.229 0.000 100.0
028 NW PRED Mean #DIV/0! #DIV/0! #DIV/0! 56.67 3.229 3.229 0.000 100.0
030 OB PRED 1 682.50 21.0 34.0 114.9 4.577 4.577 0.000 100.0
030 OB PRED 2 682.50 21.0 34.0 115.0 4.577 4.577 0.000 100.0
030 OB PRED 3 682.50 21.0 34.0 115.0 4.577 4.577 0.000 100.0
030 OB PRED Mean 682.50 21.0 34.0 114.97 4.577 4.577 0.000 100.0
%BF
Δ%BF
(pred-
meas)
%FFM FM (kg) FFM (kg) Body Volume
1st
volume
mst.
2nd
volume
mst.
3rd
volume
mst.
Density
Model Body Density BSA
Processi
ng
27.80 -0.70 72.20 26.4 68.4933 91.567 8 .109 8 .155 . Siri 1.036 21204.064 JO
28.30 -1.20 71.70 26.8 68.0096 91.647 8 .064 88.950 . Siri 1.035 21202.851 JO
. . . . . . . . . Siri . . JO
28.05 -0.95 71.95 26.61 68.251 91.607 8 .087 8 .052 . Siri 1.0355 21203.45757 JO
38.50 2.00 61.50 35.7 57.0165 91.494 89.101 89.066 . Siri 1.013 20566.140 JO
39.40 2.70 60.60 36.5 56.1778 91.652 89.226 89.257 . Siri 1.012 20564.470 JO
. . . . . . . . . Siri . . JO
38.95 2.35 61.05 36.11 56. 9716337 91.573 89.164 89.162 #DIV/0! Siri 1.012 20565.305 JO
23.60 -0.90 76.40 12.6 40.8551 51.165 49.013 49.118 . Siri 1.045 16105.696 JO
22.60 -1.20 77.40 12.1 41.3861 51.054 48.718 48.943 48.961 Siri 1.047 16105.071 JO
22.40 -1.50 77.60 12.0 41.4914 51.029 48.915 48.938 . Siri 1.048 16104.803 JO
22.86666667 -1.20 77.13 2.23 41.24422131 51.08266667 48.88212 48.9997 48.96071 Siri 1.046733333 16105.19006 JO
38.80 0.50 61.20 36.2 57.1235 92.177 89.950 90.065 . Siri 1.013 19669.237 JO
39.50 2.20 60.50 36.8 56.3211 92.064 89.826 89.965 . Siri 1.011 19647.162 JO
39.50 2.10 60.50 36.8 56.3211 92.065 89.862 89.931 . Siri 1.011 19647.159 JO
39.26666667 1.60 60.73 36.59 56. 8856602 92.102 89.87954 89.9872 #DIV/0! Siri 1.011666667 19654.51928 JO
27.30 0.80 72.70 18.1 48.2358 3.981 61.788 61.791 . Siri 1.037 17780.187 JO
27.10 0.40 72.90 18.0 48.3665 3.947 61.528 61.715 61.795 Siri 1.038 17779.878 JO
26.60 0.30 73.40 17.6 48.6952 3.879 61.605 61.770 . Siri 1.039 17779.406 JO
27 0.50 73.00 17.91 48. 3247606 63.9 66667 61.64008 61.7589 61.79542 Siri 1.0377 17779.82375 JO
15.20 -1.30 84.77 1 .6 59.3410 65.788 3.417 3.425 . Siri 1.064 18481.255 JO
14.00 -5.00 85.98 9.8 60.2250 65.666 3.230 3.367 . Siri 1.067 18486.949 JO
14.60 -6.70 85.38 1 .2 59.8 00 65.742 3.319 3.430 . Siri 1.064 18485.937 JO
14.6 -4.33 85.38 10.22 59.78866667 65.732 63.32205 63.40718 #DIV/0! Siri 1.064933333 18484.7138 JO
18.20 -2.10 81.80 1 .8 48.3560 55.919 53.817 53.835 . Siri 1.057 16373.366 JO
17.50 -3.60 82.50 1 .3 48.7726 55.833 53.711 53.769 . Siri 1.059 16373.767 JO
17.80 -2.00 82.20 1 .5 48.5939 55.866 53.801 53.746 . Siri 1.058 16373.565 JO
17.83333333 -2.57 82.17 10.54 48. 7416004 5 .87 66667 53.77644 53.78349 #DIV/0! Siri 1.0581 16373.56602 JO
31.60 -1.30 68.40 21.7 47.0746 66.962 64.723 65.062 64.880 Siri 1.028 17775.116 JO
31.80 -0.20 68.20 21.9 46.9355 66.986 64.834 64.816 . Siri 1.027 17774.894 JO
31.00 -0.60 69.00 21.3 47.4861 66.877 64.660 64.774 . Siri 1.029 17774.887 JO
31.46666667 -0.70 68.53 1.66 47.16539824 6 .94166667 64.73892 64.88397 64.8802 Siri 1.0281 17774.96553 JO
30.00 1.00 31.75 27.6 64.3640 89.168 86.767 86.677 . Siri 1.031 20615.535 JO
29.60 0.90 31.91 27.3 64.6900 89.097 86.629 86.673 . Siri 1.032 20615.096 JO
29.10 0.40 32.18 26.7 6 .2 90 89.168 86.538 86.526 . Siri 1.033 20613.854 JO
29.56666667 0.77 31.95 27.19 64.75433333 89.14433333 86.64479 86.62514 #DIV/0! Siri 1.032133333 20614.82848 JO
31.60 0.60 68.40 35.1 7 .9685 08.058 05.212 05.408 . Siri 1.028 23218.897 JO
32.10 1.80 67.90 35.7 7 .4158 08.168 05.407 05.433 . Siri 1.027 23219.243 JO
31.90 1.10 68.10 35.4 7 .6382 08.132 05.465 05.304 . Siri 1.027 23219.282 JO
31.86666667 1.17 68.13 35.39 75.67415194 108.1193333 05.3613 05.3815 #DIV/0! Siri 1.027266667 23219.14038 JO
25.70 0.20 74.30 18.5 53.3720 69.039 66.759 66.838 . Siri 1.041 18491.676 JO
24.90 -0.70 75.10 17.9 53.9405 68.908 66.569 66.766 . Siri 1.042 18490.779 JO
25.60 0.40 74.40 18.4 53.4269 68.997 66.685 66.829 . Siri 1.041 18489.198 JO
25.4 -0.03 74.60 18.24 53. 7979332 68.9 133333 66.67115 66.81077 #DIV/0! Siri 1.0412 18490.55099 JO
22.80 1.20 77.20 12.9 43.7292 54.102 52.009 52.089 . Siri 1.047 16292.293 JO
22.70 0.30 77.30 12.9 43.8221 54.131 52.138 52.019 . Siri 1.047 16298.026 JO
22.80 1.20 77.20 12.9 43.7602 54.142 52.155 52.024 . Siri 1.047 16297.192 JO
22.76666667 0.90 77.23 12.90 43.77049002 54.125 5 .10083 5 .04397 #DIV/0! Siri 1.047066667 16295.83736 JO
28.10 -0.30 71.90 32.3 82.6451 11.016 108.186 10 .916 . Siri 1.035 24358.252 .
28.30 -1.40 71.70 32.5 82.4518 11.122 108.165 108.150 . Siri 1.035 24362.854 .
30.80 2.40 69.20 35.4 79.5654 11.676 108.859 108.556 . Siri 1.030 24361.350 .
29.06666667 0.23 70.93 33.42 81.554 8979 111.2713333 108.4034 108.2073 #DIV/0! Siri 1.0333 24360.81845 .
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ID GRP Code TRIAL PB Temp RH Mass (kg) VTGp VTG
ΔVTG
(pred-
meas)
VTGpp
031 NW PRED 1 . . . 69.9 3.310 3.310 0.000 100.0
031 NW PRED 2 . . . 69.9 3.310 3.310 0.000 100.0
031 NW PRED 3 . . . 69.9 3.310 3.310 0.000 100.0
031 NW PRED Mean #DIV/0! #DIV/0! #DIV/0! 69.93 3.310 3.310 0.000 100.0
032 NW PRED 1 683.00 23.0 52.0 64.7 3.220 3.220 0.000 100.0
032 NW PRED 2 683.00 23.0 52.0 64.7 3.220 3.220 0.000 100.0
032 NW PRED 3 683.00 23.0 52.0 64.7 3.220 3.220 0.000 100.0
032 NW PRED Mean 683.00 23.0 52.0 64.73 3.220 3.220 0.000 100.0
033 NW PRED 1 683.00 23.0 52.0 53.5 3.050 3.050 0.000 100.0
033 NW PRED 2 683.00 23.0 52.0 53.5 3.050 3.050 0.000 100.0
033 NW PRED 3 683.00 23.0 52.0 53.5 3.050 3.050 0.000 100.0
033 NW PRED Mean 683.00 23.0 52.0 53.49 3.050 3.050 0.000 100.0
034 NW PRED 1 684.00 22.0 53.0 55.0 3.132 3.132 0.000 100.0
034 NW PRED 2 684.00 22.0 53.0 55.0 3.132 3.132 0.000 100.0
034 NW PRED 3 684.00 22.0 53.0 55.0 3.132 3.132 0.000 100.0
034 NW PRED Mean 684.00 22.0 53.0 54.96 3.132 3.132 0.000 100.0
035 OB PRED 1 680.20 22.0 52.0 98.4 4.115 4.115 0.000 100.0
035 OB PRED 2 680.20 22.0 52.0 98.4 4.115 4.115 0.000 100.0
035 OB PRED 3 680.20 22.0 52.0 98.3 4.115 4.115 0.000 100.0
035 OB PRED Mean 680.20 22.0 52.0 98.35 4.115 4.115 0.000 100.0
036 NW PRED 1 680.30 22.0 53.0 52.2 2.818 2.818 0.000 100.0
036 NW PRED 2 680.30 22.0 53.0 52.1 2.818 2.818 0.000 100.0
036 NW PRED 3 680.30 22.0 53.0 52.1 2.818 2.818 0.000 100.0
036 NW PRED Mean 680.30 22.0 53.0 52.15 2.818 2.818 0.000 100.0
037 NW PRED 1 . . . 65.0 3.592 3.592 0.000 100.0
037 NW PRED 2 . . . 65.0 3.592 3.592 0.000 100.0
037 NW PRED 3 . . . 65.0 3.592 3.592 0.000 100.0
037 NW PRED Mean #DIV/0! #DIV/0! #DIV/0! 64.99 3.592 3.592 0.000 100.0
038 NW PRED 1 . . . 68.1 3.615 3.615 0.000 100.0
038 NW PRED 2 . . . 68.1 3.615 3.615 0.000 100.0
038 NW PRED 3 . . . 68.0 3.615 3.615 0.000 100.0
038 NW PRED Mean #DIV/0! #DIV/0! #DIV/0! 68.06 3.615 3.615 0.000 100.0
039 NW PRED 1 688.00 22.00 53.0 60.9 3.300 3.300 0.000 100.0
039 NW PRED 2 688.00 22.00 53.0 60.9 3.300 3.300 0.000 100.0
039 NW PRED 3 688.00 22.00 53.0 60.9 3.300 3.300 0.000 100.0
039 NW PRED Mean 688.00 22.0 53.0 60.90 3.300 3.300 0.000 100.0
041 OB PRED 1 697.45 22.0 46.0 106.2 3.938 3.938 0.000 100.0
041 OB PRED 2 697.45 22.0 46.0 106.1 3.938 3.938 0.000 100.0
041 OB PRED 3 697.45 22.0 46.0 106.1 3.938 3.938 0.000 100.0
041 OB PRED Mean 697.45 22.0 46.0 106.14 3.938 3.938 0.000 100.0
042 OB PRED 1 679.45 21.0 51.0 128.7 4.860 4.860 0.000 100.0
042 OB PRED 2 679.45 21.0 51.0 128.7 4.860 4.860 0.000 100.0
042 OB PRED 3 679.45 21.0 51.0 128.7 4.860 4.860 0.000 100.0
042 OB PRED Mean 679.45 21.0 51.0 128.69 4.860 4.860 0.000 100.0
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Δ%BF
(pred-
meas)
%FFM FM (kg) FFM (kg) Body Volume
1st
volume
mst.
2nd
volume
mst.
3rd
volume
mst.
Density
Model Body Density BSA
Processi
ng
32.90 1.00 67.10 23.0 46.9223 68.221 66.100 66.021 . Siri 1.025 17911.499 JO
32.70 -1.20 67.30 22.9 47.0645 68.196 66.043 66.028 . Siri 1.026 17911.884 JO
32.60 0.10 67.40 22.8 47.1353 68.187 66.019 66.034 . Siri 1.026 17912.012 JO
32.73333333 -0.03 67.27 22.89 47.0407023 68.20133333 66.05398 66.02775 #DIV/0! Siri 1.025366667 17911.79819 JO
20.20 0.60 79.80 13.1 51.6566 61.494 59.363 59.437 . Siri 1.053 17243.235 JO
20.80 0.20 79.20 13.5 51.2664 61.565 59.435 59.508 . Siri 1.051 17242.987 JO
20.30 -0.40 79.70 13.1 51.5879 61.501 59.437 59.380 . Siri 1.053 17242.672 JO
20.43333333 0.13 79.57 13.23 51.50361873 61.52 59.41162 59.44196 #DIV/0! Siri 1.052266667 17242.96477 JO
27.40 0.20 72.63 14.6 38.8490 1.037 49.594 49.680 . Siri 1.037 15573.620 JO
26.60 1.20 73.36 14.3 39.2440 1.039 49.520 49.607 . Siri 1.039 15574.268 JO
27.60 1.00 72.44 14.6 38.7470 1.037 49.663 49.451 49.662 Siri 1.037 15574.144 JO
27.2 0.80 72.81 14.51 38.94666667 1.0373 49.59229 49.57935 49.66228 Siri 1.0373 15574.01072 JO
20.40 0.60 79.60 11.2 43.7554 52.233 50.264 50.211 . Siri 1.052 15910.310 JO
18.90 -1.20 81.10 10.4 44.5707 52.057 50.044 50.078 . Siri 1.056 15908.902 JO
19.80 0.00 80.20 10.9 44.0753 52.155 50.120 50.199 . Siri 1.054 15908.781 JO
19.7 -0.20 80.30 10.83 44.13379711 52.14833333 50.14274 50.16244 #DIV/0! Siri 1.053933333 15909.33096 JO
30.30 1.00 69.70 29.8 68.5572 95.441 92.782 92.763 . Siri 1.031 21893.034 JO
30.80 2.80 69.20 30.3 68.0654 95.541 92.851 92.895 . Siri 1.030 21893.022 JO
30.20 2.20 69.80 29.7 68.6406 95.407 92.862 92.616 . Siri 1.031 21891.003 JO
30.43333333 2.00 69.57 29.93 68.42107583 95.463 92.83177 92.75803 #DIV/0! Siri 1.030266667 21892.35306 JO
25.10 0.70 74.90 13.1 39.0618 50.060 48.195 48.276 . Siri 1.042 14934.701 JO
24.30 1.80 75.70 12.7 39.4743 49.970 48.124 48.166 . Siri 1.044 14933.945 JO
23.90 0.50 76.10 12.5 39.6818 49.920 48.098 48.511 48.093 Siri 1.045 14933.779 JO
24.43333333 1.00 75.57 12.74 39.40594732 49.98333333 48.13904 48.31775 48.09334 Siri 1.0433 14934.14182 JO
16.90 0.70 83.10 11.0 53.9771 61.271 59.033 58.991 . Siri 1.060 17605.447 JO
15.30 1.00 84.70 9.9 55.0621 61.108 58.937 59.128 58.761 Siri 1.064 17611.668 JO
16.00 1.20 84.00 10.4 54.5997 61.186 58.751 58.943 58.910 Siri 1.062 17610.655 JO
16.06666667 0.97 83.93 10.44 54.54628063 61.18833333 58.90701 59.02101 58.83583 Siri 1.062066667 17609.25696 JO
32.10 3.20 67.90 21.8 46.2071 66.283 64.003 63.990 . Siri 1.027 17995.514 JO
32.30 4.20 67.70 22.0 46.0893 66.339 63.980 64.124 . Siri 1.026 17998.564 JO
31.70 3.20 68.30 21.6 46.4751 66.219 63.673 64.009 63.856 Siri 1.028 17994.818 JO
32.03333333 3.53 67.97 21.80 46.257156 66.28033333 63.8851 64.04109 63.85556 Siri 1.026833333 17996.29865 JO
35.70 3.00 64.30 21.7 39.1455 59.737 57.609 57.807 57.643 Siri 1.019 16945.381 JO
36.70 4.30 63.30 22.4 38.5542 59.888 57.767 57.785 . Siri 1.017 16948.655 JO
35.90 4.20 64.10 21.9 39.0377 59.778 57.639 57.694 . Siri 1.019 16947.967 JO
36.1 3.83 63.90 21.98 38.91248605 59.801 57.67162 57.76205 57.64333 Siri 1.0183 16947.33433 JO
36.10 -1.80 63.90 38.3 67.8323 104.242 101.512 101.732 . Siri 1.018 22378.278 JO
37.40 0.40 62.60 39.7 66.4426 104.518 101.982 101.814 . Siri 1.016 22376.890 JO
37.10 0.70 62.90 39.4 66.7558 104.428 101.790 101.826 . Siri 1.016 22376.150 JO
36.86666667 -0.23 63.13 39.13 67.01023101 104.396 101.7614 101.7906 #DIV/0! Siri 1.0167 22377.10626 JO
32.30 -0.70 67.70 41.6 87.1264 125.404 122.074 122.405 . Siri 1.026 26134.599 JO
32.10 -0.50 67.90 41.3 87.3809 125.340 122.246 122.105 . Siri 1.027 26134.240 JO
32.00 0.80 68.00 41.2 87.5021 125.297 122.049 122.217 . Siri 1.027 26133.284 JO
32.13333333 -0.13 67.87 41.35 87.33644838 125.347 122.123 122.2425 #DIV/0! Siri 1.026633333 26134.04079 JO
ID GRP Code TRIAL PB Temp RH Mass (kg) VTGp VTG
ΔVTG
(pred-
meas)
VTGpp
031 NW PRED 1 . . . 69.9 3.310 3.310 0.000 100.0
031 NW PRED 2 . . . 69.9 3.310 3.310 0.000 100.0
031 NW PRED 3 . . . 69.9 3.310 3.310 0.000 100.0
031 NW PRED Mean #DIV/0! #DIV/0! #DIV/0! 69.93 3.31 3.31 0.000 100.0
032 NW PRED 1 683.00 23.0 52.0 64.7 3.220 3.220 0.000 100.0
032 NW PRED 2 683.00 23.0 52.0 64.7 3.220 3.220 0.000 100.0
032 NW PRED 3 683.00 23.0 52.0 64.7 3.220 3.220 0.000 100.0
032 NW PRED Mean 683.00 23.0 2.0 64.73 3.220 3.220 0.000 100.0
033 NW PRED 1 683.00 23.0 52.0 53.5 3.050 3.050 0.000 100.0
033 NW PRED 2 683.00 23.0 52.0 53.5 3.050 3.050 0.000 100.0
033 NW PRED 3 683.00 23.0 52.0 53.5 3.050 3.050 0.000 100.0
033 NW PRED Mean 683.00 23.0 52.0 53.49 3.050 3.050 0.000 100.0
034 NW PRED 1 684.00 22.0 53.0 5 .0 3.132 3.132 0.000 100.0
034 NW PRED 2 684.00 22. 53.0 5 .0 3.132 3.132 0.000 100.0
034 NW PRED 3 684.00 22. 53.0 5 .0 3.132 3.132 0.000 100.0
034 NW PRED Mean 684.00 22.0 5 .0 54.96 3.132 3.132 0.000 100.0
035 OB PRED 1 680.20 22.0 52.0 98.4 4.115 4.115 0.000 100.0
035 OB PRED 2 680.20 22. 52.0 98.4 4.115 4.115 0.000 100.0
035 OB PRED 3 680.20 22.0 52.0 98.3 4.115 4.115 0.000 100.0
035 OB PRED Mean 680.20 2 .0 5 . 98.35 4.115 4.115 0.000 100.0
036 NW PRED 1 680.30 22.0 53.0 52.2 2.81 2.818 0.000 100.0
036 NW PRED 2 680.30 22.0 53.0 52.1 2.81 2.818 0.000 100.0
036 NW PRED 3 680.30 22.0 53.0 52.1 2.81 2.818 0.000 100.0
036 NW PRED Mean 680.30 22.0 53.0 52.15 2.818 2.818 0.00 100.0
037 NW PRED 1 . . . 65.0 3.592 3.592 0.000 100.0
037 NW PRED 2 . . . 65.0 3.592 3.592 0.000 100.0
037 NW PRED 3 . . . 65.0 3.592 3.592 0.000 100.0
037 NW PRED Mean #DIV/0! #DIV/0! #DIV/0! 64.99 3. 92 3.592 0.000 100.0
038 NW PRED 1 . . . 68.1 3.615 3.615 0.000 100.0
038 NW PRED 2 . . . 68.1 3.615 3.615 0.000 100.0
038 NW PRED 3 . . . 68.0 3.615 3.615 0.000 100.0
038 NW PRED Mean #DIV/0! #DIV/0! #DIV/0! 8.06 3. 15 3.615 0.000 100.0
039 NW PRED 1 688.00 22.00 53.0 60.9 3.300 3.300 0.000 100.0
039 NW PRED 2 688.00 22.00 53.0 60.9 3.300 3.300 0.000 100.0
039 NW PRED 3 688.00 22.00 53.0 60.9 3.300 3.300 0.000 100.0
039 NW PRED Mean 688.00 2 .0 53.0 60. 0 3.300 3.300 0.000 100.0
041 OB PRED 1 697.45 22.0 46.0 106.2 3.938 3.938 0.000 100.0
041 OB PRED 2 697.45 22.0 46.0 106.1 3.938 3.938 0.000 100.0
041 OB PRED 3 697.45 22.0 46.0 106.1 3.938 3.938 0.000 100.0
041 OB PRED Mean 697.45 22.0 46.0 106.14 3.938 3.938 0.000 100.0
042 OB PRED 1 679.45 21.0 51.0 128.7 4.860 4.860 0.000 100.0
042 OB PRED 2 679.45 21.0 51.0 128.7 4.860 4.860 0.000 100.0
042 OB PRED 3 679.45 21.0 51. 128.7 4.860 4.860 0.000 100.0
042 OB PRED Mean 679.45 21.0 51.0 128.69 4.860 4.860 0.000 100.0
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Screen Captures of Raw Data from VTGmeas:
ID GRP Code Order TRIAL Mass (kg) VTGp VTG
ΔVTG
(pred-
meas)
VTGpp
014 OB MS 2 1 94.9 3.869 4.099 -0.230 105.9
014 OB MS 2 2 94.8 3.869 4.295 -0.426 111.0
014 OB MS 2 3 . 3.869 . . .
014 OB MS 2 Mean 94.85 3.869 4.197 -0.328 108.5
015 OB MS 1 1 92.7 3.624 2.167 1.457 59.8
015 OB MS 1 2 92.7 3.624 2.386 1.238 65.8
015 OB MS 1 3 . 3.624 . . .
015 OB MS 1 Mean 92.69 3.624 2.277 1.348 62.8
016 NW MS 2 1 53.5 3.376 3.933 -0.557 116.5
016 NW MS 2 2 53.5 3.376 4.015 -0.639 118.9
016 NW MS 2 3 53.4 3.376 3.937 -0.561 116.6
016 NW MS 2 Mean 53.46 3.376 3.962 -0.586 117.3
019 OB MS 2 1 93.1 3.127 2.373 0.754 75.9
019 OB MS 2 2 93.1 3.127 2.130 0.997 68.1
019 OB MS 2 3 93.1 3.127 2.279 0.848 72.9
019 OB MS 2 Mean 93.07 3.127 2.261 0.866 72.3
020 NW MS . 1 66.3 3.403 3.086 0.317 90.7
020 NW MS . 2 66.3 3.403 3.314 0.089 97.4
020 NW MS . 3 66.3 3.403 3.205 0.198 94.2
020 NW MS . Mean 66.33 3.403 3.202 0.201 94.1
021 NW MS . 1 69.9 3.760 4.995 -1.235 132.8
021 NW MS . 2 70.0 3.760 5.003 -1.243 133.1
021 NW MS . 3 70.0 3.760 5.700 -1.940 151.6
021 NW MS . Mean 69.96 3.760 5.233 -1.473 139.2
022 NW MS 2 1 59.1 3.320 4.223 -0.903 127.2
022 NW MS 2 2 59.1 3.320 4.284 -0.964 129.0
022 NW MS 2 3 59.1 3.320 4.128 -0.808 124.3
022 NW MS 2 Mean 59.13 3.320 4.212 -0.892 126.9
023 NW MS 2 1 68.8 3.326 3.762 -0.436 113.1
023 NW MS 2 2 68.8 3.326 3.373 -0.047 101.4
023 NW MS 2 3 68.8 3.326 3.395 -0.069 102.1
023 NW MS 2 Mean 68.80 3.326 3.510 -0.184 105.5
024 OB MS 2 1 91.9 3.709 3.554 0.155 95.8
024 OB MS 2 2 91.9 3.709 3.554 0.155 95.8
024 OB MS 2 3 91.9 3.709 3.687 0.022 99.4
024 OB MS 2 Mean 91.90 3.709 3.598 0.111 97.0
025 OB MS 2 1 111.1 4.159 3.963 0.196 95.3
025 OB MS 2 2 111.1 4.159 3.772 0.387 90.7
025 OB MS 2 3 111.0 4.159 3.991 0.168 96.0
025 OB MS 2 Mean 111.05 4.159 3.909 0.250 94.0
027 NW MS 2 1 72.0 3.442 3.405 0.037 98.9
027 NW MS 2 2 72.0 3.442 3.177 0.265 92.3
027 NW MS 2 3 72.0 3.442 3.418 0.024 99.3
027 NW MS 2 Mean 71.96 3.442 3.333 0.109 96.8
028 NW MS 2 1 56.7 3.229 2.959 0.270 91.6
028 NW MS 2 2 56.7 3.229 3.089 0.140 95.7
028 NW MS 2 3 56.7 3.229 2.960 0.269 91.7
028 NW MS 2 Mean 56.68 3.229 3.003 0.226 93.0
030 OB MS 2 1 114.9 4.577 3.998 0.579 87.3
030 OB MS 2 2 115.0 4.577 4.932 -0.355 107.8
030 OB MS 2 3 115.0 4.577 4.694 -0.117 102.6
030 OB MS 2 Mean 114.97 4.577 4.541 0.036 99.2
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ID GRP Code Order TRIAL Mass (kg) VTGp VTG
ΔVTG
(pred-
meas)
VTGpp
014 OB MS 2 1 94.9 3.869 4.099 -0.230 105.9
014 OB MS 2 2 94.8 3.869 4.295 -0.426 111.0
014 OB MS 2 3 . 3.869 . . .
014 OB MS 2 Mean 94.85 3.869 4.197 -0.328 108.5
015 OB MS 1 1 92.7 3.624 2.167 1.457 59.8
015 OB MS 1 2 92.7 3.624 2.386 1.238 65.8
015 OB MS 1 3 . 3.624 . . .
015 OB MS 1 Mean 92.69 3.624 2.277 1.348 62.8
016 NW MS 2 1 53.5 3.376 3.933 -0.557 116.5
016 NW MS 2 2 53.5 3.376 4.015 -0.639 118.9
016 NW MS 2 3 53.4 3.376 3.937 -0.561 116.6
016 NW MS 2 Mean 53.46 3.376 3.962 -0.586 117.3
019 OB MS 2 1 93.1 3.127 2.373 0.754 75.9
019 OB MS 2 2 93.1 3.127 2.130 0.997 68.1
019 OB MS 2 3 93.1 3.127 2.279 0.848 72.9
019 OB MS 2 Mean 93.07 3.127 2.261 0.866 72.3
020 NW MS . 1 66.3 3.403 3.086 0.317 90.7
020 NW MS . 2 66.3 3.403 3.314 0.089 97.4
020 NW MS . 3 66.3 3.403 3.205 0.198 94.2
020 NW MS . Mean 66.33 3.403 3.202 0.201 94.1
021 NW MS . 1 69.9 3.760 4.995 -1.235 132.8
021 NW MS . 2 70.0 3.760 5.003 -1.243 133.1
021 NW MS . 3 70.0 3.760 5.700 -1.940 151.6
021 NW MS . Mean 69.96 3.760 5.233 -1.473 139.2
022 NW MS 2 1 59.1 3.320 4.223 -0.903 127.2
022 NW MS 2 2 59.1 3.320 4.284 -0.964 129.0
022 NW MS 2 3 59.1 3.320 4.128 -0.808 124.3
022 NW MS 2 Mean 59.13 3.320 4.212 -0.892 126.9
023 NW MS 2 1 68.8 3.326 3.762 -0.436 113.1
023 NW MS 2 2 68.8 3.326 3.373 -0.047 101.4
023 NW MS 2 3 68.8 3.326 3.395 -0.069 102.1
023 NW MS 2 Mean 68.80 3.326 3.510 -0.184 105.5
024 OB MS 2 1 91.9 3.709 3.554 0.155 95.8
024 OB MS 2 2 91.9 3.709 3.554 0.155 95.8
024 OB MS 2 3 91.9 3.709 3.687 0.022 99.4
024 OB MS 2 Mean 91.90 3.709 3.598 0.111 97.0
025 OB MS 2 1 111.1 4.159 3.963 0.196 95.3
025 OB MS 2 2 111.1 4.159 3.772 0.387 90.7
025 OB MS 2 3 111.0 4.159 3.991 0.168 96.0
025 OB MS 2 Mean 111.05 4.159 3.909 0.250 94.0
027 NW MS 2 1 72.0 3.442 3.405 0.037 98.9
027 NW MS 2 2 72.0 3.442 3.177 0.265 92.3
027 NW MS 2 3 72.0 3.442 3.418 0.024 99.3
027 NW MS 2 Mean 71.96 3.442 3.333 0.109 96.8
028 NW MS 2 1 56.7 3.229 2.959 0.270 91.6
028 NW MS 2 2 56.7 3.229 3.089 0.140 95.7
028 NW MS 2 3 56.7 3.229 2.960 0.269 91.7
028 NW MS 2 Mean 56.68 3.229 3.003 0.226 93.0
030 OB MS 2 1 114.9 4.577 3.998 0.579 87.3
030 OB MS 2 2 115.0 4.577 4.932 -0.355 107.8
030 OB MS 2 3 115.0 4.577 4.694 -0.117 102.6
030 OB MS 2 Mean 114.97 4.577 4.541 0.036 99.2
%BF
Δ%BF
(pred-
meas)
%FFM FM (kg) FFM (kg) Body Volume
1st
volume
mst.
2nd
volume
mst.
3rd
volume
mst.
Density
Model Body Density BSA
Processi
ng
28.50 -0.70 71.50 27.0 67.8331 91.716 89.121 89.052 . Siri 1.034 21204.569 JO
29.50 -1.20 70.50 28.0 6 .8574 91.869 89.135 89.186 . Siri 1.032 21200.935 JO
. . . . . . . . . Siri . . JO
29 -0.95 71.00 27.51 67.3452120 91.7925 89.1279 89.1189 #DIV/0! Siri 1.03335 21202.75218 JO
36.50 2.00 63.50 33.8 58.8622 91.101 88.868 89.261 89.288 Siri 1.018 20564.876 JO
36.70 2.70 63.30 34.0 58.6715 91.138 88.886 89.178 89.269 Siri 1.017 20564.088 JO
. . . . . . . . . Siri . . JO
36.6 2.35 63.40 33.93 58.76685027 91.1195 88.87697 89.21948 89.27818 #DIV/0! 1.01725 20564.48207 JO
24.50 -0.90 75.50 13.1 40.3675 51.249 48.912 48.936 . Siri 1.014 16104.624 JO
23.80 -1.20 76.20 12.7 40.7360 51.172 48.777 48.851 . Siri 1.045 16103.656 JO
23.90 -1.50 76.10 12.8 40.6747 51.175 48.868 48.828 . Siri 1.044 16102.337 JO
24.06666667 -1.20 75.93 12.87 40.59277016 51.19866667 48.85212 48.87194 #DIV/0! #DIV/0! 1.034466667 16103.53895 JO
38.30 0.50 61.70 35.6 57.4264 91.819 89. 09 90.020 89.884 Siri 1.014 19645.437 JO
37.30 2.20 62.70 34.7 58.3532 91.613 89.857 89.831 . Siri 1.016 19644.884 JO
37.40 2.10 62.60 34.8 58.2532 91.620 89. 90 89.792 . Siri 1.016 19643.880 JO
37.66666667 1.60 62.33 35.05 58.01091753 91.684 89.78528 89.88111 89.88407 #DIV/0! 1.0151 19644.73392 JO
26.50 0.80 73.50 17.6 8.7552 63.860 61.5 7 61.779 61.811 Siri 1.039 17778.429 JO
26.70 0.40 73.30 17.7 8.6206 63.878 61.730 61.715 . Siri 1.038 17778.128 JO
26.30 0.30 73.70 17.4 8.8830 63.827 61.717 61.713 . Siri 1.039 17777.676 JO
26.5 0.50 73.50 17.58 48.75294419 63.855 61.65128 61.73556 61.81133 Siri 1.038766667 17778.07774 JO
16.50 -1.30 83.48 11.5 58.3870 65.916 62.978 63.133 . Siri 1.061 18474.752 JO
19.00 -5.00 81.00 13.3 5 .6760 66.295 63.415 63.646 63.447 Siri 1.055 18478.103 JO
21.30 -6.70 78.70 14.9 55.0595 66.614 63.457 63.485 . Siri 1.050 18477.075 JO
18.93333333 -4.33 81.06 13.25 56.7 748188 66.275 63.2831 63.42117 63.44747 Siri 1.055566667 18476.64355 JO
20.30 -2.10 79.70 12.0 47.1320 56.191 53.791 53.684 . Siri 1.052 16375.934 JO
21.10 -3.60 78.90 12.5 46.6524 56.273 53.830 53.759 . Siri 1.051 16374.970 JO
19.80 -2.00 80.20 11.7 47.4158 56.114 53.664 53.732 . Siri 1.054 16374.200 JO
20.4 -2.57 79.60 12.06 47.06675138 56.19266667 53.762 53.72499 #DIV/0! Siri 1.052233333 16375.03469 JO
32.90 -1.30 67.10 22.6 46.1686 67.130 64.718 64.873 . Siri 1.025 17773.272 JO
32.00 -0.20 68.00 22.0 46.7868 66.999 64.790 64.850 . Siri 1.027 17773.095 JO
31.60 -0.60 68.40 21.7 47.0573 66.939 64.717 64.785 . Siri 1.028 17772.349 JO
32.16666667 -0.70 67.83 22.13 46.67090287 67.02266667 64.74178 64.83581 #DIV/0! Siri 1.026566667 17772.90509 JO
29.00 1.00 71.05 26.7 65.3120 88.947 86.611 86.516 . Siri 1.034 20612.990 JO
28.70 0.90 71.33 26.4 65.5460 88.860 86.481 86.471 . Siri 1.034 20609.571 JO
28.70 0.40 71.30 26.4 65.5145 88.868 86.414 86.448 . Siri 1.034 20609.014 JO
28.8 0.77 71.23 26.47 65.45749372 88.89166667 86.50178 86.47821 #DIV/0! Siri 1.033866667 20610.52538 JO
31.00 0.60 69.00 34.4 76.6263 107.913 105.222 105.264 . Siri 1.029 23217.797 JO
30.30 1.80 69.70 33.6 77.4043 107.752 105.033 105.284 . Siri 1.031 23217.879 JO
30.80 1.10 69.20 34.2 76.8400 107.846 105.183 105.146 . Siri 1.030 23216.720 JO
30.7 1.17 69.30 34.09 76.9568871 107.837 105.1 62 105.2317 #DIV/0! Siri 1.029766667 23217.46539 JO
25.50 0.20 74.50 18.4 53.6185 69.133 66. 6 66.828 . Siri 1.041 18506.779 JO
25.60 -0.70 74.40 18.4 53.5393 69.136 66. 98 67.003 . Siri 1.041 18505.712 JO
25.20 0.40 74.80 18.1 53.8244 69.076 66. 20 66.768 . Siri 1.042 18505.306 JO
25.43333333 -0.03 74.57 18.30 53.66072741 69.115 66.96815 66.86609 #DIV/0! Siri 1.041233333 18505.93208 JO
21.60 1.20 78.40 12.2 44.4410 54.0 8 52.065 52.061 . Siri 1.050 16297.299 JO
22.40 0.30 77.60 12.7 43.9816 54.088 52.105 52.078 . Siri 1.048 16296.361 JO
21.60 1.20 78.40 12.2 44.4386 53.999 52.091 52.017 . Siri 1.050 16296.915 JO
21.86666667 0.90 78.13 12.39 44. 8707758 54.03166667 52.08695 52.05217 #DIV/0! Siri 1.049066667 16296.85816 JO
28.40 -0.30 71.60 32.6 82.2747 111.051 108.399 108.230 . Siri 1.035 24355.035 JO
29.70 -1.40 70.30 34.2 80.8622 111.460 108.483 108.216 . Siri 1.032 24365.451 JO
28.40 2.40 71.60 32.6 82.3135 111.1 3 107.980 108.195 . Siri 1.035 24359.916 JO
28.83333333 0.23 71.17 33.15 81.81676653 111.2046667 108.2874 108.2136 #DIV/0! Siri 1.0338 24360.13401 JO
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ID GRP Code Order TRIAL Mass (kg) VTGp VTG
ΔVTG
(pred-
meas)
VTGpp
031 NW MS 2 1 70.0 3.310 3.220 0.090 97.3
031 NW MS 2 2 69.9 3.310 3.637 -0.327 109.9
031 NW MS 2 3 69.9 3.310 3.264 0.046 98.6
031 NW MS 2 Mean 69.95 3.310 3.374 -0.064 101.9
032 NW MS 2 1 64.7 3.220 3.267 -0.047 101.5
032 NW MS 2 2 64.7 3.220 3.284 -0.064 102.0
032 NW MS 2 3 64.7 3.220 3.227 -0.007 100.2
032 NW MS 2 Mean 64.75 3.220 3.259 -0.039 101.2
033 NW MS 2 1 53.5 3.050 2.802 0.248 91.9
033 NW MS 2 2 53.5 3.050 2.657 0.393 87.1
033 NW MS 2 3 53.5 3.050 2.723 0.327 89.3
033 NW MS 2 Mean 53.52 3.050 2.727 0.323 89.4
034 OB MS 2 1 55.0 3.132 3.320 -0.188 106.0
034 OB MS 2 2 54.9 3.132 3.424 -0.292 109.3
034 OB MS 2 3 54.9 3.132 3.311 -0.179 105.7
034 OB MS 2 Mean 54.94 3.132 3.352 -0.220 107.0
035 OB MS 2 1 98.3 4.115 3.143 0.972 76.4
035 OB MS 2 2 98.3 4.115 2.683 1.432 65.2
035 OB MS 2 3 98.3 4.115 2.878 1.237 69.9
035 OB MS 2 Mean 98.31 4.115 2.901 1.214 70.5
036 NW MS 2 1 52.2 2.818 2.364 0.454 83.9
036 NW MS 2 2 52.2 2.818 2.096 0.722 74.4
036 NW MS 2 3 52.2 2.818 2.385 0.433 84.6
036 NW MS 2 Mean 52.16 2.818 2.282 0.536 81.0
037 NW MS 2 1 65.0 3.592 3.852 -0.260 107.2
037 NW MS 2 2 65.0 3.592 3.457 0.135 96.2
037 NW MS 2 3 65.0 3.592 3.784 -0.192 105.3
037 NW MS 2 Mean 64.98 3.592 3.698 -0.106 102.9
038 NW MS 2 1 68.0 3.615 3.013 0.602 83.3
038 NW MS 2 2 68.1 3.615 2.950 0.665 81.6
038 NW MS 2 3 68.0 3.615 2.911 0.704 80.5
038 NW MS 2 Mean 68.04 3.615 2.958 0.657 81.8
039 NW MS 2 1 61.0 3.300 2.225 1.075 67.4
039 NW MS 2 2 61.0 3.300 2.163 1.137 65.5
039 NW MS 2 3 61.0 3.300 2.204 1.096 66.8
039 NW MS 2 Mean 60.99 3.300 2.197 1.103 66.6
041 OB MS 2 1 106.1 3.938 3.956 -0.018 100.5
041 OB MS 2 2 106.1 3.938 3.627 0.311 92.1
041 OB MS 2 3 106.1 3.938 3.699 0.239 93.9
041 OB MS 2 Mean 106.12 3.938 3.761 0.177 95.5
042 OB MS 2 1 128.7 4.860 5.300 -0.440 109.1
042 OB MS 2 2 128.7 4.860 4.986 -0.126 102.6
042 OB MS 2 3 128.6 4.860 3.963 0.897 81.5
042 OB MS 2 Mean 128.65 4.86 4.750 0.110 97.7
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ID GRP Code Order TRIAL Mass (kg) VTGp VTG
ΔVTG
(pred-
meas)
VTGpp
031 NW MS 2 1 70.0 3.310 3.220 0.090 97.3
031 NW MS 2 2 69.9 3.310 3.637 -0.327 109.9
031 NW MS 2 3 69.9 3.310 3.264 0.046 98.6
031 NW MS 2 Mean 69.95 3.310 3.374 -0.064 101.9
032 NW MS 2 1 64.7 3.220 3.267 -0.047 101.5
032 NW MS 2 2 64.7 3.220 3.284 -0.064 102.0
032 NW MS 2 3 64.7 3.220 3.227 -0.007 100.2
032 NW MS 2 Mean 64.75 3.220 3.259 -0.039 101.2
033 NW MS 2 1 53.5 3.050 2.802 0.248 91.9
033 NW MS 2 2 53.5 3.050 2.657 0.393 87.1
033 NW MS 2 3 53.5 3.050 2.723 0.327 89.3
033 NW MS 2 Mean 53.52 3.050 2.727 0.323 89.4
034 OB MS 2 1 55.0 3.132 3.320 -0.188 106.0
034 OB MS 2 2 54.9 3.132 3.424 -0.292 109.3
034 OB MS 2 3 54.9 3.132 3.311 -0.179 105.7
034 OB MS 2 Mean 54.94 3.132 3.352 -0.220 107.0
035 OB MS 2 1 98.3 4.115 3.143 0.972 76.4
035 OB MS 2 2 98.3 4.115 2.683 1.432 65.2
035 OB MS 2 3 98.3 4.115 2.878 1.237 69.9
035 OB MS 2 Mean 98.31 4.115 2.901 1.214 70.5
036 NW MS 2 1 52.2 2.818 2.364 0.454 83.9
036 NW MS 2 2 52.2 2.818 2.096 0.722 74.4
036 NW MS 2 3 52.2 2.818 2.385 0.433 84.6
036 NW MS 2 Mean 52.16 2.818 2.282 0.536 81.0
037 NW MS 2 1 65.0 3.592 3.852 -0.260 107.2
037 NW MS 2 2 65.0 3.592 3.457 0.135 96.2
037 NW MS 2 3 65.0 3.592 3.784 -0.192 105.3
037 NW MS 2 Mean 64.98 3.592 3.698 -0.106 102.9
038 NW MS 2 1 68.0 3.615 3.013 0.602 83.3
038 NW MS 2 2 68.1 3.615 2.950 0.665 81.6
038 NW MS 2 3 68.0 3.615 2.911 0.704 80.5
038 NW MS 2 Mean 68.04 3.615 2.958 0.657 81.8
039 NW MS 2 1 61.0 3.300 2.225 1.075 67.4
039 NW MS 2 2 61.0 3.300 2.163 1.137 65.5
039 NW MS 2 3 61.0 3.300 2.204 1.096 66.8
039 NW MS 2 Mean 60.99 3.300 2.197 1.103 66.6
041 OB MS 2 1 106.1 3.938 3.956 -0.018 100.5
041 OB MS 2 2 106.1 3.938 3.627 0.311 92.1
041 OB MS 2 3 106.1 3.938 3.699 0.239 93.9
041 OB MS 2 Mean 106.12 3.938 3.761 0.177 95.5
042 OB MS 2 1 128.7 4.860 5.300 -0.440 109.1
042 OB MS 2 2 128.7 4.860 4.986 -0.126 102.6
042 OB MS 2 3 128.6 4.860 3.963 0.897 81.5
042 OB MS 2 Mean 128.65 4.86 4.750 0.110 97.7
%BF
Δ%BF
(pred-
meas)
%FFM FM (kg) FFM (kg) Body Volume
1st
volume
mst.
2nd
volume
mst.
3rd
volume
mst.
Density
Model Body Density BSA
Processi
ng
31.90 1.00 68.10 22.3 47.6418 68.107 66.067 65.898 . Siri 1.027 17914.730 JO
33.90 -1.20 66.10 23.7 46.2333 68.374 66.061 66.105 . Siri 1.023 17913.201 JO
32.50 0.10 67.50 22.7 47.2123 68.177 66.049 66.021 . Siri 1.026 17913.160 JO
32.76666667 -0.03 67.23 22.92 47.02915708 68.21933333 66.05884 66.00826 #DIV/0! Siri 1.025366667 17913.69683 JO
19.60 0.60 80.40 12.7 5 .0586 61.429 59.667 59.290 59.344 Siri 1.054 17245.159 JO
20.60 0.20 79.40 13.3 51.4088 61.55 59.487 59.375 . Siri 1.052 17244.830 JO
20.70 -0.40 79.30 13.4 51.3395 61.563 59.545 59.389 . Siri 1.052 17244.182 JO
20.3 0.13 79.70 13.14 51.6 23208 61.514 59.56633 59.3514 59.34392 Siri 1.052533333 17244.72338 JO
27.20 0.20 72.80 14.6 38.9720 51.606 49.604 49.783 49.732 Siri 1.037 15579.009 JO
25.40 1.20 74.60 13.6 39.9291 51.400 49.642 49.577 . Siri 1.041 15577.935 JO
26.60 1.00 73.40 14.2 39.2801 51.524 49.630 49.785 . Siri 1.039 15576.794 JO
26.4 0.80 73.60 14.13 39.39372777 51.51 49.6253 49.71488 49.73238 Siri 1.039066667 15577.91267 JO
19.80 0.60 80.20 1 .9 44.0751 52.161 49.521 50.023 50.158 Siri 1.054 15908.758 JO
20.10 -1.20 79.90 11.0 4 .8979 52.18 50.23 50.026 50.110 Siri 1.053 15906.859 JO
19.80 0.00 80.20 10.9 44.0566 52.135 50.092 50.044 . Siri 1.054 15905.913 JO
19.9 -0.20 80.10 10.93 44.00987879 52.15866667 49.95 67 50.03104 50.1339 Siri 1.0534 15907.17669 JO
29.30 1.00 70.70 28.8 69.5170 95.207 92.913 92.942 . Siri 1.033 21889.838 JO
28.00 2.80 72.00 27.5 70.7813 94.932 92.818 92.854 . Siri 1.036 21888.006 JO
28.00 2.20 72.00 27.5 70.7676 94.921 92.721 92.774 . Siri 1.036 21886.211 JO
28.43333333 2.00 71.57 27.95 70.35528577 95.02 92.8174 92.8567 #DIV/0! Siri 1.034633333 21888.01827 JO
24.40 0.70 75.60 1 .7 39.4422 49.996 48.420 48.287 . Siri 48.420 14937.169 JO
22.50 1.80 77.50 11.7 40.4247 49.789 48.469 48.278 48.229 Siri 48.469 14935.797 JO
23.40 0.50 76.60 1 .2 39.9524 49.882 48.306 48.155 . Siri 48.306 14935.343 JO
23.43333333 1.00 76.57 12.22 39.93974011 49.889 48.39823 48.2399 48.22876 Siri 48.39822795 14936.10331 JO
16.20 0.70 83.80 1 .5 4.4645 61.216 58.8 6 58.901 . Siri 1.062 17609.947 JO
14.30 1.00 85.70 9.3 5.6920 60.950 58.699 58.952 58.791 Siri 1.662 17608.955 JO
14.80 1.20 85.20 9.6 5.3585 61.01 58.9 8 58.643 58.705 Siri 1.065 17607.797 JO
15.1 0.97 84.90 . 1 55.1716670 61.05866667 58.80415 58.83199 58.74812 Siri 1.2629 17608.89968 JO
28.90 3.20 71.10 19.7 48.3757 65.829 63.729 63.839 . Siri 1.034 17994.086 JO
28.10 4.20 71.90 19.1 48.9314 65.736 63.708 63.724 . Siri 1.035 17995.864 JO
28.50 3.20 71.50 19.4 48.6444 65.762 63.754 63.761 . Siri 1.035 17993.550 JO
28.5 3.53 71.50 19.39 48.6 05046 65.77566667 63.73029 63.77465 #DIV/0! Siri 1.034466667 17994.5002 JO
32.70 3.00 67.30 19.9 41.0249 59.449 57.708 57.826 . Siri 1.025 16954.698 JO
32.40 4.30 67.60 19.8 41.2460 59.460 57.785 57.821 . Siri 1.026 16961.376 JO
31.70 4.20 68.30 19.3 41.6702 59.371 57.897 57.646 57.748 Siri 1.028 16960.882 JO
32.26666667 3.83 67.73 1 .68 41.3136994 59.42666667 57.79 78 57.7641 57.74847 Siri 1.026366667 16958.98522 JO
37.90 -1.80 62.10 40.2 65.8982 104.586 101.992 101.925 . Siri 1.015 22374.915 JO
37.00 0.40 63.00 39.3 66.8640 104.411 102.032 101.798 . Siri 1.017 22376.444 JO
36.40 0.70 63.60 38.6 67.4871 104.271 101.724 101.769 . Siri 1.018 22374.517 JO
37.1 -0.23 62.90 39.37 66.7497853 104.4226667 101. 159 101.8306 #DIV/0! Siri 1.016266667 22375.29232 JO
33.00 -0.70 67.00 42.5 .2075 125.544 122.168 122.240 . Siri 1.025 26132.282 JO
32.60 -0.50 67.40 41.9 .7122 125.436 122.299 122.145 . Siri 1.026 26131.010 JO
31.20 0.80 68.80 40.1 8.5008 125.043 121. 9 122.281 122.194 Siri 1.029 26129.428 JO
32.26666667 -0.13 67.73 41. 1 87 14017667 125.341 122.1205 122.2217 122.1941 Siri 1.0264 26130.9067 JO
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Screen Captures of Raw Data from DXA:
ID GRP Code Status  Area (cm2) Larm
 Area (cm2)
R arm
 Area (cm2)
L Ribs
 Area (cm2)
R Ribs
 Area (cm2) T
Spine
 Area (cm2) L
Spine
 Area (cm2)
Pelvis
 Area (cm2) L
Leg
 Area (cm2)
R leg
 Area (cm2)
Subtotal
 Area (cm2)
Head
 Area (cm2)
Total
014 OB DXA Completed 262.5 265.75 139.97 169.19 143.63 61.26 269.8 428.04 409.37 2149.51 278.32 2427.83
015 OB DXA Completed 233.7 235.32 129.83 142.41 138.35 52.74 215.84 372.86 378.94 1899.99 235.32 2135.31
016 NW DXA Completed 175.27 182.57 107.11 122.93 127.8 35.3 230.86 357.44 374.48 1713.76 250.33 1964.09
019 OB DXA Completed 210.16 205.7 151.33 190.28 144.84 32.05 172.84 348.92 343.24 1799.37 233.7 2033.07
020 NW DXA Completed 215.84 218.68 140.38 139.97 133.08 42.19 233.29 392.33 400.45 1916.22 232.07 2148.29
021 NW DXA Completed 243.84 246.68 144.84 146.47 143.63 47.88 283.6 403.93 43.88 2091.49 273.86 2365.35
022 NW DXA Completed 205.29 205.29 95.75 101.02 121.72 38.54 176.08 327.42 329.45 1600.57 277.92 1878.49
023 NW DXA Completed 215.03 202.05 119.69 123.74 127.8 58.83 238.16 389.49 390.3 1865.1 247.49 2112.59
024 OB DXA Completed 247.9 268.99 147.28 128.21 146.87 52.74 246.68 409.78 421.95 2070.39 262.5 2332.89
025 OB DXA Completed 279.54 296.18 172.03 134.7 154.17 64.1 299.42 498.23 484.43 2382.8 251.55 2634.35
027 NW DXA Completed 195.56 214.63 104.68 101.43 127.4 43.41 249.92 377.73 371.64 1786.39 303.48 2089.87
028 NW DXA Completed 182.28 202.89 133.78 114.78 115.99 40.01 250.98 349.6 366.98 1757.3 245.73 2003.03
030 OB DXA Completed 293.42 311.61 105.08 142.67 145.5 77.19 280.49 512.07 539.56 2407.59 266.34 2673.93
031 NW DXA Completed 207.74 221.88 138.22 127.72 134.59 52.14 221.88 356.47 363.75 1824.39 238.86 2063.25
032 NW DXA Completed 198.85 186.32 132.16 117.61 139.03 33.14 246.54 361.32 364.15 1779.12 254.22 2033.34
033 NW DXA Completed 165.71 167.32 119.63 118.82 120.44 35.16 212.59 328.99 318.88 1587.55 237.65 1825.19
034 NW DXA Completed 175.41 183.89 114.38 113.57 115.19 40.42 255.03 335.45 331.01 1664.34 264.73 1929.06
035 OB DXA Completed 280.08 301.91 145.09 143.88 136.2 50.92 234.82 458.72 456.7 2208.34 267.15 2475.49
036 NW DXA Completed 176.62 185.51 89.32 115.19 118.02 37.18 186.72 278.87 295.85 1483.27 261.49 1744.77
037 NW DXA Completed 243.31 263.11 109.12 115.99 121.25 46.88 264.79 368.19 372.64 1905.22 272 2177.22
038 NW DXA Completed 231.99 223.91 133.78 115.59 134.18 50.12 217.84 378.3 358.49 1844.19 249.77 2093.96
039 NW DXA Completed 178.64 187.13 124.89 130.14 124.48 40.01 187.53 348.98 347.98 1669.19 245.33 1914.51
041 OB DXA Completed 247.35 253.41 161.66 152.77 144.29 45.27 217.84 382.34 408.61 2013.53 250.18 2263.71
042 OB DXA Completed 302.31 302.31 168.54 120.84 178.24 69.11 246.54 494.29 484.59 2366.77 244.11 2610.89
ID GRP Code Status  Area (cm2) Larm
 Area (cm2)
R arm
 Area (cm2)
L Ribs
 Area (cm2)
R Ribs
 Area (cm2) T
Spine
 Area (cm2) L
Spine
 Area (cm2)
Pelvis
 Area (cm2) L
Leg
 Area (cm2)
R leg
 Area (cm2)
Subtotal
 Area (cm2)
Head
 Area (cm2)
Total
014 OB DXA Completed 262.5 265.75 139.97 169.19 143.63 61.26 269.8 428.04 409.37 2149.51 278.32 2427.83
015 OB DXA Completed 233.7 235.32 129.83 142.41 138.35 52.74 215.84 372.86 378.94 1899.99 235.32 2135.31
016 NW DXA Completed 175.27 182.57 107.11 122.93 127.8 35.3 230.86 357.44 374.48 1713.76 250.33 1964.09
019 OB DXA Completed 210.16 205.7 151.33 190.28 144.84 32.05 172.84 348.92 343.24 1799.37 233.7 2033.07
020 NW DXA Completed 215.84 218.68 140.38 139.97 133.08 42.19 233.29 392.33 400.45 1916.22 232.07 2148.29
021 NW DXA Completed 243.84 246.68 144.84 146.47 143.63 47.88 283.6 403.93 43.88 2091.49 273.86 2365.35
022 NW DXA Completed 205.29 205.29 95.75 101.02 121.72 38.54 176.08 327.42 329.45 1600.57 277.92 1878.49
023 NW DXA Completed 215.03 202.05 119.69 123.74 127.8 58.83 238.16 389.49 390.3 1865.1 247.49 2112.59
024 OB DXA Completed 247.9 268.99 147.28 128.21 146.87 52.74 246.68 409.78 421.95 2070.39 262.5 2332.89
025 OB DXA Completed 279.54 296.18 172.03 134.7 154.17 64.1 299.42 498.23 484.43 2382.8 251.55 2634.35
027 NW DXA Completed 195.56 214.63 104.68 101.43 127.4 43.41 249.92 377.73 371.64 1786.39 303.48 2089.87
028 NW DXA Completed 182.28 202.89 133.78 114.78 115.99 40.01 250.98 349.6 366.98 1757.3 245.73 2003.03
030 OB DXA Completed 293.42 311.61 105.08 142.67 145.5 77.19 280.49 512.07 539.56 2407.59 266.34 2673.93
031 NW DXA Completed 207.74 221.88 138.22 127.72 134.59 52.14 221.88 356.47 363.75 1824.39 238.86 2063.25
032 NW DXA Completed 198.85 186.32 132.16 117.61 139.03 33.14 246.54 361.32 364.15 1779.12 254.22 2033.34
033 NW DXA Completed 165.71 167.32 119.63 118.82 120.44 35.16 212.59 328.99 318.88 1587.55 237.65 1825.19
034 NW DXA Completed 175.41 183.89 114.38 113.57 115.19 40.42 255.03 335.45 331.01 1664.34 264.73 1929.06
035 OB DXA Completed 280.08 301.91 145.09 143.88 136.2 50.92 234.82 458.72 456.7 2208.34 267.15 2475.49
036 NW DXA Completed 176.62 185.51 89.32 115.19 118.02 37.18 186.72 278.87 295.85 1483.27 261.49 1744.77
037 NW DXA Completed 243.31 263.11 109.12 115.99 121.25 46.88 264.79 368.19 372.64 1905.22 272 2177.22
038 NW DXA Completed 231.99 223.91 133.78 115.59 134.18 50.12 217.84 378.3 358.49 1844.19 249.77 2093.96
039 NW DXA Completed 178.64 187.13 124.89 130.14 124.48 40.01 187.53 348.98 347.98 1669.19 245.33 1914.51
041 OB DXA Completed 247.35 253.41 161.66 152.77 144.29 45.27 217.84 382.34 408.61 2013.53 250.18 2263.71
042 OB DXA Completed 302.31 302.31 168.54 120.84 178.24 69.11 246.54 494.29 484.59 2366.77 244.11 2610.89
BMC (g) L
arm
BMC (g) R
arm
BMC (g) L
Ribs
BMC (g) R
Ribs
BMC (g) T
Spine
BMC (g) L
Spine
BMC (g)
Pelvis
BMC (g) L
Leg
BMC (g) R
leg
BMC (g)
Subtotal
BMC (g)
Head
BMC (g)
Total
BMC M PP
(%)
BMC F PP
(%)
230.89 235.53 86.4 102.97 124.97 63.12 363.17 553.58 531.21 2291.85 622.9 2914.75 107.75 137.23
178.87 184.63 78.15 81.03 97.43 47.47 255.89 428.5 447.58 1799.55 459.35 2258.9 83.51 106.35
124.78 312.71 58.17 65.96 102.23 35.93 268.61 395.04 409.55 1593.01 505.19 2098.2 76.16 96.38
214.99 154.31 81.62 109.45 119.58 27.84 225.27 398.82 382.56 1714.42 445.7 2160.14 79.86 101.70
160.89 170.66 85.7 89.3 122.6 50.08 344.17 454.67 462.42 1940.49 601.04 2541.53 93.95674677 119.66
206.75 207.95 98.04 97.66 12913 59.84 365.98 508.92 559.28 2233.56 658.14 2891.7 106.9020333 136.14
153.21 153.78 50.58 54.56 97.99 35.32 174.82 357.15 357.24 1434.65 530.74 1965.39 275500 90.28
163.79 152.67 77.12 76.22 106.26 72.1 324.76 498.59 470.94 1942.44 656.91 2599.35 93.90715318 118.26
202.64 223.01 96.62 82.96 141.41 52.72 362.46 506.4 512.28 2180.51 568.3 2748.8 101.6192237 129.42
257.35 275.65 131.29 100.37 152.47 81.33 442.45 659.37 596.7 2696.98 658.48 3355.46 124.0465804 157.98
147.22 156.42 68.03 57.64 108.9 45.78 293.37 388.94 386.5 1652.79 669.7 2322.49 85.85914972 109.35
121.55 143.47 79.19 60.21 83.14 37.52 265.59 367.78 368.65 1527.11 512.43 2039.54 5.39889094 96.02
289.38 316.21 86.67 110.22 187.42 94.31 470.05 749.57 764.87 3068.71 655.46 3724.17 136.2168983 173.06
151.85 166.23 91.53 80.26 113.79 53.85 281.11 399.47 410.36 1748.43 580.04 2328.47 275500 106.96
152.54 138.89 87.64 78.58 130.11 39.97 355.89 440.93 443.21 1867.77 612.56 2480.32 91.69390018 116.78
126.68 131.97 68.8 65.87 106.02 41.1 295.37 370.47 371.05 1577.33 457.55 2034.89 7 .22698706 95.80
123.42 133.2 65.15 64.83 100.71 41.42 277.62 387.42 374.25 1568.02 647.99 2216.01 81.92273567 104.33
239.74 261.74 101.12 95.81 122.18 45.93 287.88 519.23 516.27 2189.91 583.95 2773.86 01.4579371 128.90
133.81 148.71 53.89 66.58 102.24 41.19 217.96 284.8 313.01 1362.19 555.97 133.81 4.94676525 6.30
209.44 225.73 76.85 70.68 108.2 50.35 315.76 453.69 460.6 1971.31 641.99 2613.3 96.60998152 123.04
157.19 154.48 81.73 67.54 90.91 46.59 226.63 374.38 344.42 1543.88 494.95 2038.83 5.37264325 95.99
130.65 135.75 70.12 68.28 100.5 40.13 231.8 390.13 383.42 1550.77 556.9 2107 77.89279113 99.20
211.74 224.18 104.6 95.7 127.08 49.2 297.59 427.9 2010.93 538.6 2549.53 2549.53 94.25249538 120.03
279.08 279.08 113.42 72.09 149.67 67.46 360.39 751.81 660.35 2733.34 460.35 3193.69 6.8138259 148.41
ID GRP Code Status  Area (cm2) Larm
 Area (cm2)
R arm
 Area (cm2)
L Ribs
 Area (cm2)
R Ribs
 Area (cm2) T
Spine
 Area (cm2) L
Spine
 Area (cm2)
Pelvis
 Area (cm2) L
Leg
 Area (cm2)
R leg
 Area (cm2)
Subtotal
 Area (cm2)
Head
 Area (cm2)
Total
014 OB DXA Completed 262.5 265.75 139.97 169.19 143.63 61.26 269.8 428.04 409.37 2149.51 278.32 2427.83
015 OB DXA Completed 233.7 235.32 129.83 142.41 138.35 52.74 215.84 372.86 378.94 1899.99 235.32 2135.31
016 NW DXA Completed 175.27 182.57 107.11 122.93 127.8 35.3 230.86 357.44 374.48 1713.76 250.33 1964.09
019 OB DXA Completed 210.16 205.7 151.33 190.28 144.84 32.05 172.84 348.92 343.24 1799.37 233.7 2033.07
020 NW DXA Completed 215.84 218.68 140.38 139.97 133.08 42.19 233.29 392.33 400.45 1916.22 232.07 2148.29
021 NW DXA Completed 243.84 246.68 144.84 146.47 143.63 47.88 283.6 403.93 43.88 2091.49 273.86 2365.35
022 NW DXA Completed 205.29 205.29 95.75 101.02 121.72 38.54 176.08 327.42 329.45 1600.57 277.92 1878.49
023 NW DXA Completed 215.03 202.05 119.69 123.74 127.8 58.83 238.16 389.49 390.3 1865.1 247.49 2112.59
024 OB DXA Completed 247.9 268.99 147.28 128.21 146.87 52.74 246.68 409.78 421.95 2070.39 262.5 2332.89
025 OB DXA Completed 279.54 296.18 172.03 134.7 154.17 64.1 299.42 498.23 484.43 2382.8 251.55 2634.35
027 NW DXA Completed 195.56 214.63 104.68 101.43 127.4 43.41 249.92 377.73 371.64 1786.39 303.48 2089.87
028 NW DXA Completed 182.28 202.89 133.78 114.78 115.99 40.01 250.98 349.6 366.98 1757.3 245.73 2003.03
030 OB DXA Completed 293.42 311.61 105.08 142.67 145.5 77.19 280.49 512.07 539.56 2407.59 266.34 2673.93
031 NW DXA Completed 207.74 221.88 138.22 127.72 134.59 52.14 221.88 356.47 363.75 1824.39 238.86 2063.25
032 NW DXA Completed 198.85 186.32 132.16 117.61 139.03 33.14 246.54 361.32 364.15 1779.12 254.22 2033.34
033 NW DXA Completed 165.71 167.32 119.63 118.82 120.44 35.16 212.59 328.99 318.88 1587.55 237.65 1825.19
034 NW DXA Completed 175.41 183.89 114.38 113.57 115.19 40.42 255.03 335.45 331.01 1664.34 264.73 1929.06
035 OB DXA Completed 280.08 301.91 145.09 143.88 136.2 50.92 234.82 458.72 456.7 2208.34 267.15 2475.49
036 NW DXA Completed 176.62 185.51 89.32 115.19 118.02 37.18 186.72 278.87 295.85 1483.27 261.49 1744.77
037 NW DXA Completed 243.31 263.11 109.12 115.99 121.25 46.88 264.79 368.19 372.64 1905.22 272 2177.22
038 NW DXA Completed 231.99 223.91 133.78 115.59 134.18 50.12 217.84 378.3 358.49 1844.19 249.77 2093.96
039 NW DXA Completed 178.64 187.13 124.89 130.14 124.48 40.01 187.53 348.98 347.98 1669.19 245.33 1914.51
041 OB DXA Completed 247.35 253.41 161.66 152.77 144.29 45.27 217.84 382.34 408.61 2013.53 250.18 2263.71
042 OB DXA Completed 302.31 302.31 168.54 120.84 178.24 69.11 246.54 494.29 484.59 2366.77 244.11 2610.89
BMD (g/cm2)
L arm
BMD (g/cm2)
R arm
BMD (g/cm2)
L Ribs
BMD (g/cm2)
R Ribs
BMD (g/cm2)
T Spine
BMD (g/cm2)
L Spine
BMD (g/cm2)
Pelvis
BMD (g/cm2)
L Leg
BMD (g/cm2)
R leg
BMD (g/cm2)
Subtotal
BMD (g/cm2)
Head
BMD (g/cm2)
Total
BMD M PP
(%)
BMD F PP
(%)
0.88 0.886 0.617 0.609 0.87 1.03 1.346 1.293 1.298 1.066 2.238 1.201 101.350211 109.7806216
0.765 0.785 0.602 0.569 0.704 0.9 1.186 1.149 1.181 0.947 1.952 1.058 89.28270042 96.70932358
0.712 0.727 0.543 0.537 0.8 1.018 1.164 1.104 1.094 0.93 2.018 1.068 88.85191348 95.78475336
1.023 0.75 0.539 0.575 0.826 0.869 1.303 1.143 1.115 0.953 1.907 1.063 89.70464135 97.16636197
0.745 0.78 0.611 0.638 0.921 1.187 1.475 1.159 1.155 1.013 2.59 1.183 99.83122363 108.1352834
0.848 0.843 0.677 0.667 0.667 0.899 1.25 1.29 1.261 1.298 1.068 1.223 103.2067511 111.7915905
0.746 0.749 0.528 0.54 0.805 0.916 0.993 1.091 1.084 0.896 1.91 1.046 87.02163062 93.81165919
0.762 0.756 0.644 0.616 0.831 1.225 1.364 1.28 1.207 1.041 2.654 1.23 102.6711185 109.6256684
0.817 0.829 0.656 0.647 0.963 1 1.469 1.236 1.214 1.053 2.165 1.178 99.40928 7 107.678245
0.921 0.931 0.763 0.745 0.989 1.269 1.478 1.323 1.232 1.132 2.618 1.274 107.5105485 116.4533821
0.753 0.729 0.65 0.568 0.855 1.055 1.174 1.03 1.04 0.925 2.207 1.111 93.75527426 101.5539305
0.667 0.707 0.592 0.525 0.717 0.938 1.058 1.052 1.005 0.869 2.085 1.018 85.907173 93.05301645
0.986 1.015 0.825 0.773 1.288 1.222 1.676 1.464 1.418 1.275 2.461 1.393 116.4715719 125.9493671
0.731 0.749 0.662 0.628 0.845 1.033 1.267 1.121 1.128 0.958 2.428 1.129 93.92678869 101.2556054
0.767 0.745 0.663 0.668 0.936 1.206 1.444 1.22 1.217 1.05 2.41 1.22 102.9535865 111.5173675
0.764 0.789 0.575 0.554 0.88 1.169 1.389 1.126 1.164 0.994 1.925 1.115 94.092827 101.9195612
0.704 0.724 0.57 0.571 0.874 1.025 1.089 1.155 1.131 0.942 2.448 1.149 96.96202532 105.0274223
0.856 0.867 0.697 0.666 0.897 0.902 1.226 1.132 1.13 0.992 2.186 1.121 93.72909699 101.3562387
0.758 0.802 0.603 0.578 0.866 1.108 1.167 1.021 1.058 0.918 2.126 1.099 92.74261603 100.4570384
0.861 0.858 0.704 0.609 0.892 1.074 1.193 1.232 1.236 1.035 2.36 1.2 101.2658228 109.6892139
0.678 0.69 0.611 0.584 0.677 0.93 1.04 0.99 0.961 0.837 1.982 0.974 82.19409283 89.03107861
0.731 0.725 0.561 0.525 0.807 1.003 1.236 1.12 1.102 0.929 2.27 1.101 92.91139241 100.6398537
0.856 0.885 0.647 0.626 0.881 1.087 1.366 1.119 1.157 0.999 2.153 1.126 95.02109705 102.9250457
0.923 0.923 0.673 0.597 0.84 0.976 1.462 1.521 1.363 1.155 1.866 1.223 02.2575251 110.5786618
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ID GRP Code Status  Area (cm2) Larm
 Area (cm2)
R arm
 Area (cm2)
L Ribs
 Area (cm2)
R Ribs
 Area (cm2) T
Spine
 Area (cm2) L
Spine
 Area (cm2)
Pelvis
 Area (cm2) L
Leg
 Area (cm2)
R leg
 Area (cm2)
Subtotal
 Area (cm2)
Head
 Area (cm2)
Total
014 OB DXA Completed 262.5 265.75 139.97 169.19 143.63 61.26 269.8 428.04 409.37 2149.51 278.32 2427.83
015 OB DXA Completed 233.7 235.32 129.83 142.41 138.35 52.74 215.84 372.86 378.94 1899.99 235.32 2135.31
016 NW DXA Completed 175.27 182.57 107.11 122.93 127.8 35.3 230.86 357.44 374.48 1713.76 250.33 1964.09
019 OB DXA Completed 210.16 205.7 151.33 190.28 144.84 32.05 172.84 348.92 343.24 1799.37 233.7 2033.07
020 NW DXA Completed 215.84 218.68 140.38 139.97 133.08 42.19 233.29 392.33 400.45 1916.22 232.07 2148.29
021 NW DXA Completed 243.84 246.68 144.84 146.47 143.63 47.88 283.6 403.93 43.88 2091.49 273.86 2365.35
022 NW DXA Completed 205.29 205.29 95.75 101.02 121.72 38.54 176.08 327.42 329.45 1600.57 277.92 1878.49
023 NW DXA Completed 215.03 202.05 119.69 123.74 127.8 58.83 238.16 389.49 390.3 1865.1 247.49 2112.59
024 OB DXA Completed 247.9 268.99 147.28 128.21 146.87 52.74 246.68 409.78 421.95 2070.39 262.5 2332.89
025 OB DXA Completed 279.54 296.18 172.03 134.7 154.17 64.1 299.42 498.23 484.43 2382.8 251.55 2634.35
027 NW DXA Completed 195.56 214.63 104.68 101.43 127.4 43.41 249.92 377.73 371.64 1786.39 303.48 2089.87
028 NW DXA Completed 182.28 202.89 133.78 114.78 115.99 40.01 250.98 349.6 366.98 1757.3 245.73 2003.03
030 OB DXA Completed 293.42 311.61 105.08 142.67 145.5 77.19 280.49 512.07 539.56 2407.59 266.34 2673.93
031 NW DXA Completed 207.74 221.88 138.22 127.72 134.59 52.14 221.88 356.47 363.75 1824.39 238.86 2063.25
032 NW DXA Completed 198.85 186.32 132.16 117.61 139.03 33.14 246.54 361.32 364.15 1779.12 254.22 2033.34
033 NW DXA Completed 165.71 167.32 119.63 118.82 120.44 35.16 212.59 328.99 318.88 1587.55 237.65 1825.19
034 NW DXA Completed 175.41 183.89 114.38 113.57 115.19 40.42 255.03 335.45 331.01 1664.34 264.73 1929.06
035 OB DXA Completed 280.08 301.91 145.09 143.88 136.2 50.92 234.82 458.72 456.7 2208.34 267.15 2475.49
036 NW DXA Completed 176.62 185.51 89.32 115.19 118.02 37.18 186.72 278.87 295.85 1483.27 261.49 1744.77
037 NW DXA Completed 243.31 263.11 109.12 115.99 121.25 46.88 264.79 368.19 372.64 1905.22 272 2177.22
038 NW DXA Completed 231.99 223.91 133.78 115.59 134.18 50.12 217.84 378.3 358.49 1844.19 249.77 2093.96
039 NW DXA Completed 178.64 187.13 124.89 130.14 124.48 40.01 187.53 348.98 347.98 1669.19 245.33 1914.51
041 OB DXA Completed 247.35 253.41 161.66 152.77 144.29 45.27 217.84 382.34 408.61 2013.53 250.18 2263.71
042 OB DXA Completed 302.31 302.31 168.54 120.84 178.24 69.11 246.54 494.29 484.59 2366.77 244.11 2610.89
Fat Mass (g)
L Arm
Fat Mass (g)
R Arm
Fat Mass (g)
Trunk
Fat Mass (g)
L Leg
Fat Mass (g)
R Leg
Fat Mass (g)
Subtotal
Fat Mass (g)
Head
Fat Mass (g)
Total
Fat Mass (g)
Android
Fat Mass (g)
Gynoid
1728 1728 12572 4347 4266 24640 1704 26344 2116 4239
1896 2016 14093 5648 5806 29459 1300 30759 2659 5609
708 674 4176 3025 3362 11944 1124 13069 615 3026
1883 1955 18407 4692 4644 31581 1456 33037 2932 4988
1337 1300 7460 3998 4409 18503 1138 19641 1172 3971
854 864 6868 2702 2909 14197 1307 15504 1208 3115
904 846 4465 2605 2736 11557 1372 12929 665 2212
1473 1365 9920 4786 5070 22614 1149 23764 1573 4786
1685 1682 12508 4340 4393 24608 1473 26081 2148 4575
2198 2295 15810 6363 6492 33157 1569 34756 2930 5919
1052 1028 6424 3743 3981 16228 1473 17701 1122 3961
796 864 4258 2825 2797 11540 1143 12684 679 3072
2334 2362 16524 5418 5235 31874 1771 33644 3105 5155
1267 1295 11892 4533 4654 23642 1074 24716 2112 5083
936 842 5970 2815 3035 13598 1169 14767 842 2958
878 897 6708 2699 2859 14041 1047 15087 1014 2854
795 733 4044 3025 2121 11718 1213 12931 636 2974
1759 1786 13107 5009 5397 27057 1453 28510 2378 4543
814 901 4358 2877 2835 11784 1159 12943 780 2728
787 937 4570 2366 2625 11285 1297 12582 781 2380
1697 1696 8323 4737 4621 21074 1187 22261 1218 4341
1209 1164 9086 3223 3413 18096 1225 19320 1283 3157
2336 2528 187778 6035 6337 36014 1891 37905 3170 5607
3075 3075 19934 7166 7246 40496 1430 41926 3854 6698
ID GRP Code Status  Area (cm2) Larm
 Area (cm2)
R arm
 Area (cm2)
L Ribs
 Area (cm2)
R Ribs
 Area (cm2) T
Spine
 Area (cm2) L
Spine
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014 OB DXA Completed 262.5 265.75 139.97 169.19 143.63 61.26 269.8 428.04 409.37 2149.51 278.32 2427.83
015 OB DXA Completed 233.7 235.32 129.83 142.41 138.35 52.74 215.84 372.86 378.94 1899.99 235.32 2135.31
016 NW DXA Completed 175.27 182.57 107.11 122.93 127.8 35.3 230.86 357.44 374.48 1713.76 250.33 1964.09
019 OB DXA Completed 210.16 205.7 151.33 190.28 144.84 32.05 172.84 348.92 343.24 1799.37 233.7 2033.07
020 NW DXA Completed 215.84 218.68 140.38 139.97 133.08 42.19 233.29 392.33 400.45 1916.22 232.07 2148.29
021 NW DXA Completed 243.84 246.68 144.84 146.47 143.63 47.88 283.6 403.93 43.88 2091.49 273.86 2365.35
022 NW DXA Completed 205.29 205.29 95.75 101.02 121.72 38.54 176.08 327.42 329.45 1600.57 277.92 1878.49
023 NW DXA Completed 215.03 202.05 119.69 123.74 127.8 58.83 238.16 389.49 390.3 1865.1 247.49 2112.59
024 OB DXA Completed 247.9 268.99 147.28 128.21 146.87 52.74 246.68 409.78 421.95 2070.39 262.5 2332.89
025 OB DXA Completed 279.54 296.18 172.03 134.7 154.17 64.1 299.42 498.23 484.43 2382.8 251.55 2634.35
027 NW DXA Completed 195.56 214.63 104.68 101.43 127.4 43.41 249.92 377.73 371.64 1786.39 303.48 2089.87
028 NW DXA Completed 182.28 202.89 133.78 114.78 115.99 40.01 250.98 349.6 366.98 1757.3 245.73 2003.03
030 OB DXA Completed 293.42 311.61 105.08 142.67 145.5 77.19 280.49 512.07 539.56 2407.59 266.34 2673.93
031 NW DXA Completed 207.74 221.88 138.22 127.72 134.59 52.14 221.88 356.47 363.75 1824.39 238.86 2063.25
032 NW DXA Completed 198.85 186.32 132.16 117.61 139.03 33.14 246.54 361.32 364.15 1779.12 254.22 2033.34
033 NW DXA Completed 165.71 167.32 119.63 118.82 120.44 35.16 212.59 328.99 318.88 1587.55 237.65 1825.19
034 NW DXA Completed 175.41 183.89 114.38 113.57 115.19 40.42 255.03 335.45 331.01 1664.34 264.73 1929.06
035 OB DXA Completed 280.08 301.91 145.09 143.88 136.2 50.92 234.82 458.72 456.7 2208.34 267.15 2475.49
036 NW DXA Completed 176.62 185.51 89.32 115.19 118.02 37.18 186.72 278.87 295.85 1483.27 261.49 1744.77
037 NW DXA Completed 243.31 263.11 109.12 115.99 121.25 46.88 264.79 368.19 372.64 1905.22 272 2177.22
038 NW DXA Completed 231.99 223.91 133.78 115.59 134.18 50.12 217.84 378.3 358.49 1844.19 249.77 2093.96
039 NW DXA Completed 178.64 187.13 124.89 130.14 124.48 40.01 187.53 348.98 347.98 1669.19 245.33 1914.51
041 OB DXA Completed 247.35 253.41 161.66 152.77 144.29 45.27 217.84 382.34 408.61 2013.53 250.18 2263.71
042 OB DXA Completed 302.31 302.31 168.54 120.84 178.24 69.11 246.54 494.29 484.59 2366.77 244.11 2610.89
Lean+ BMC
(g) L Arm
Lean+ BMC
(g) R Arm
Lean+ BMC
(g) Trunk
Lean+ BMC
(g) L Leg
Lean+ BMC
(g) R Leg
Lean+ BMC
(g) Subtotal
Lean+ BMC
(g) Head
Lean+ BMC
(g) Total
Lean+ BMC
(g) Android
Lean+ BMC
(g) Gynoid
4733 4921 33561 11146 10887 65247 5163 70410 4143 9885
37.61 38.7 30441 10635 10515 59222 3886 63108 4202 10387
1921 2057 20250 6780 6852 37860 3489 54418 3349 9157
3592 3840 29674 9814 10489 57410 4164 61573 4127 9956
2267 2439 23031 7959 8532 44228 3586 47814 2914 7366
3384 3362 25464 9336 9870 51417 4117 55535 3134 8433
2916 2970 22125 7362 7527 42901 4207 47108 2679 6366
2224 2337 22202 7809 7902 42473 3646 46119 2964 7221
3895 4419 32908 10552 11307 63081 4449 67530 4798 9852
4594 5251 36358 14030 13697 73931 4791 78722 5619 12262
2831 2951 25271 9662 9502 50217 4592 54808 3165 8177
1996 2437 22063 7404 7396 41296 3553 44849 3038 6954
5964 6366 38369 13493 14136 78328 5268 83597 5146 11096
2254 2500 23746 7071 7409 42980 3397 46377 3131 7282
2793 2631 24221 8985 9140 47770 3688 51458 3058 8355
2193 2401 18653 6423 6597 36266 3241 39507 2153 5943
2283 2516 19748 7328 7598 39472 3839 43311 2591 6928
5228 5537 34041 11279 11053 67138 4461 71600 4629 9845
2268 2502 18210 6383 6975 36338 3648 39986 2174 5339
3761 4039 24602 8197 8982 49581 4135 53716 3359 8129
2256 2381 23019 7381 7424 42460 3644 46104 3015 7346
2096 2342 20497 6974 6937 38846 3786 42633 2510 6033
4720 5199 32254 10571 11487 65230 5270 69501 4446 10284
5898 5898 43498 15269 14513 85076 4128 89204 7089 13721
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R arm
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L Ribs
 Area (cm2)
R Ribs
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014 OB DXA Completed 262.5 265.75 139.97 169.19 143.63 61.26 269.8 428.04 409.37 2149.51 278.32 2427.83
015 OB DXA Completed 233.7 235.32 129.83 142.41 138.35 52.74 215.84 372.86 378.94 1899.99 235.32 2135.31
016 NW DXA Completed 175.27 182.57 107.11 122.93 127.8 35.3 230.86 357.44 374.48 1713.76 250.33 1964.09
019 OB DXA Completed 210.16 205.7 151.33 190.28 144.84 32.05 172.84 348.92 343.24 1799.37 233.7 2033.07
020 NW DXA Completed 215.84 218.68 140.38 139.97 133.08 42.19 233.29 392.33 400.45 1916.22 232.07 2148.29
021 NW DXA Completed 243.84 246.68 144.84 146.47 143.63 47.88 283.6 403.93 43.88 2091.49 273.86 2365.35
022 NW DXA Completed 205.29 205.29 95.75 101.02 121.72 38.54 176.08 327.42 329.45 1600.57 277.92 1878.49
023 NW DXA Completed 215.03 202.05 119.69 123.74 127.8 58.83 238.16 389.49 390.3 1865.1 247.49 2112.59
024 OB DXA Completed 247.9 268.99 147.28 128.21 146.87 52.74 246.68 409.78 421.95 2070.39 262.5 2332.89
025 OB DXA Completed 279.54 296.18 172.03 134.7 154.17 64.1 299.42 498.23 484.43 2382.8 251.55 2634.35
027 NW DXA Completed 195.56 214.63 104.68 101.43 127.4 43.41 249.92 377.73 371.64 1786.39 303.48 2089.87
028 NW DXA Completed 182.28 202.89 133.78 114.78 115.99 40.01 250.98 349.6 366.98 1757.3 245.73 2003.03
030 OB DXA Completed 293.42 311.61 105.08 142.67 145.5 77.19 280.49 512.07 539.56 2407.59 266.34 2673.93
031 NW DXA Completed 207.74 221.88 138.22 127.72 134.59 52.14 221.88 356.47 363.75 1824.39 238.86 2063.25
032 NW DXA Completed 198.85 186.32 132.16 117.61 139.03 33.14 246.54 361.32 364.15 1779.12 254.22 2033.34
033 NW DXA Completed 165.71 167.32 119.63 118.82 120.44 35.16 212.59 328.99 318.88 1587.55 237.65 1825.19
034 NW DXA Completed 175.41 183.89 114.38 113.57 115.19 40.42 255.03 335.45 331.01 1664.34 264.73 1929.06
035 OB DXA Completed 280.08 301.91 145.09 143.88 136.2 50.92 234.82 458.72 456.7 2208.34 267.15 2475.49
036 NW DXA Completed 176.62 185.51 89.32 115.19 118.02 37.18 186.72 278.87 295.85 1483.27 261.49 1744.77
037 NW DXA Completed 243.31 263.11 109.12 115.99 121.25 46.88 264.79 368.19 372.64 1905.22 272 2177.22
038 NW DXA Completed 231.99 223.91 133.78 115.59 134.18 50.12 217.84 378.3 358.49 1844.19 249.77 2093.96
039 NW DXA Completed 178.64 187.13 124.89 130.14 124.48 40.01 187.53 348.98 347.98 1669.19 245.33 1914.51
041 OB DXA Completed 247.35 253.41 161.66 152.77 144.29 45.27 217.84 382.34 408.61 2013.53 250.18 2263.71
042 OB DXA Completed 302.31 302.31 168.54 120.84 178.24 69.11 246.54 494.29 484.59 2366.77 244.11 2610.89
Total Mass
(g) L Arm
Total Mass
(g) R Arm
Total Mass
(g) Trunk
Total Mass
(g) L Leg
Total Mass
(g) R Leg
Total Mass
(g) Subtotal
Total Mass
(g) Head
Total Mass
(g) Total
Total Mass
(g) Android
Total Mass
(g) Gynoid
6460 6659 46132 15493 15154 89888 6867 96754 6259 14124
5656 5886 44534 16283 34.7 88681 5185 93866 6861 15996
2629 2731 24426 9804 10214 49805 4613 54418 0.3349 9157
5476 5795 48080 14506 15134 88991 5620 94610 7059 14944
3605 3739 30490 11957 12940 62731 4724 67455 4086 11337
4239 4226 32333 12039 12788 65614 5424 71039 4342 11549
3820 3816 26590 9967 10263 54457 5580 60037 3345 8578
3697 3702 32121 12595 12972 65087 4796 69883 4537 12008
5580 6101 45416 14891 15700 87689 5921 93611 6946 14428
6792 7546 52168 20392 20189 107087 6360 113448 8548 18181
3883 3979 31695 13404 13483 66444 6065 72509 4287 12138
2793 3301 26320 10229 10193 52836 4697 57532 3716 10026
8298 8729 54894 18911 19371 110202 7039 117241 8251 16250
3521 3795 35637 11604 12064 66622 4471 71092 5244 12365
3729 3473 30192 11800 12174 61368 4858 66226 3900 11313
3070 3298 25361 9121 9457 50307 4287 54594 3167 8797
3078 3248 23791 10353 10718 51190 5052 56241 3227 9902
6987 7323 47148 16287 16450 94195 5914 100110 706 14388
3081 3403 22567 9260 9810 48122 4807 52929 2953 8067
4548 4976 29172 10563 11607 60866 5432 66298 4140 10510
3952 4077 31342 12118 12045 63534 4830 68364 4234 11687
3305 3506 29583 101998 10350 56942 5011 61953 3794 9190
7057 7727 51032 16606 17824 100245 7161 107405 7616 15891
8973 8973 63432 22435 21759 125572 5558 131129 10943 20419
66
ID GRP Code Status  Area (cm2) Larm
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R arm
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R Ribs
 Area (cm2) T
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014 OB DXA Completed 262.5 265.75 139.97 169.19 143.63 61.26 269.8 428.04 409.37 2149.51 278.32 2427.83
015 OB DXA Completed 233.7 235.32 129.83 142.41 138.35 52.74 215.84 372.86 378.94 1899.99 235.32 2135.31
016 NW DXA Completed 175.27 182.57 107.11 122.93 127.8 35.3 230.86 357.44 374.48 1713.76 250.33 1964.09
019 OB DXA Completed 210.16 205.7 151.33 190.28 144.84 32.05 172.84 348.92 343.24 1799.37 233.7 2033.07
020 NW DXA Completed 215.84 218.68 140.38 139.97 133.08 42.19 233.29 392.33 400.45 1916.22 232.07 2148.29
021 NW DXA Completed 243.84 246.68 144.84 146.47 143.63 47.88 283.6 403.93 43.88 2091.49 273.86 2365.35
022 NW DXA Completed 205.29 205.29 95.75 101.02 121.72 38.54 176.08 327.42 329.45 1600.57 277.92 1878.49
023 NW DXA Completed 215.03 202.05 119.69 123.74 127.8 58.83 238.16 389.49 390.3 1865.1 247.49 2112.59
024 OB DXA Completed 247.9 268.99 147.28 128.21 146.87 52.74 246.68 409.78 421.95 2070.39 262.5 2332.89
025 OB DXA Completed 279.54 296.18 172.03 134.7 154.17 64.1 299.42 498.23 484.43 2382.8 251.55 2634.35
027 NW DXA Completed 195.56 214.63 104.68 101.43 127.4 43.41 249.92 377.73 371.64 1786.39 303.48 2089.87
028 NW DXA Completed 182.28 202.89 133.78 114.78 115.99 40.01 250.98 349.6 366.98 1757.3 245.73 2003.03
030 OB DXA Completed 293.42 311.61 105.08 142.67 145.5 77.19 280.49 512.07 539.56 2407.59 266.34 2673.93
031 NW DXA Completed 207.74 221.88 138.22 127.72 134.59 52.14 221.88 356.47 363.75 1824.39 238.86 2063.25
032 NW DXA Completed 198.85 186.32 132.16 117.61 139.03 33.14 246.54 361.32 364.15 1779.12 254.22 2033.34
033 NW DXA Completed 165.71 167.32 119.63 118.82 120.44 35.16 212.59 328.99 318.88 1587.55 237.65 1825.19
034 NW DXA Completed 175.41 183.89 114.38 113.57 115.19 40.42 255.03 335.45 331.01 1664.34 264.73 1929.06
035 OB DXA Completed 280.08 301.91 145.09 143.88 136.2 50.92 234.82 458.72 456.7 2208.34 267.15 2475.49
036 NW DXA Completed 176.62 185.51 89.32 115.19 118.02 37.18 186.72 278.87 295.85 1483.27 261.49 1744.77
037 NW DXA Completed 243.31 263.11 109.12 115.99 121.25 46.88 264.79 368.19 372.64 1905.22 272 2177.22
038 NW DXA Completed 231.99 223.91 133.78 115.59 134.18 50.12 217.84 378.3 358.49 1844.19 249.77 2093.96
039 NW DXA Completed 178.64 187.13 124.89 130.14 124.48 40.01 187.53 348.98 347.98 1669.19 245.33 1914.51
041 OB DXA Completed 247.35 253.41 161.66 152.77 144.29 45.27 217.84 382.34 408.61 2013.53 250.18 2263.71
042 OB DXA Completed 302.31 302.31 168.54 120.84 178.24 69.11 246.54 494.29 484.59 2366.77 244.11 2610.89
% Fat L Arm % Fat R Arm % Fat Trunk % Fat L Leg % Fat R Leg % FatSubtotal % Fat Head % Fat Total % Fat M PP % Fat F PP
26.7 26 27.3 28.1 28.2 27.4 24.8 27.2 116.24 77.49
33.5 34.3 31.6 34.7 35.6 33.2 25.1 32.8 140.17 93.45
26.9 24.7 17.1 30.9 32.9 24 24.4 24 93.39 64.86
34.4 33.7 383 32.3 30.7 35.5 25.9 34.9 149.15 99.43
37.1 34.8 24.5 33.4 34.1 29.5 24.1 29.1 124.36 82.91
20.2 20.4 21.2 22.4 2.8 21.6 24.1 21.8 93.16 62.11
23.7 22.2 16.8 26.1 26.7 21.2 24.6 21.5 83.66 58.11
39.9 36.9 30.9 38 39.1 34.7 24 34 123.64 87.40
30.2 27.6 27.5 29.1 28 28.1 24.9 27.9 119.23 79.49
32.4 30.4 30.3 31.2 32.2 31 24.7 30.6 130.77 87.18
27.1 25.8 20.3 27.9 29.5 24.4 24.3 24.4 104.27 69.52
28.5 26.2 16.2 27.6 27.4 21.8 24.3 22 94.02 62.68
28.1 27.1 30.1 28.7 27 28.9 25.2 28.7 116.67 79.72
36 34.1 33.4 39.1 38.6 35.5 24 34.8 135.41 94.05
25.1 24.2 19.8 23.9 24.9 22.2 24.1 22.3 95.30 63.53
28.6 27.2 26.5 29.6 30.2 27.9 24.4 27.6 117.95 78.63
25.8 22.6 17 29.2 29.1 22.9 24 23 98.29 65.53
25.2 24.4 27.8 30.8 32.8 28.7 24.6 28.5 115.85 79.17
26.4 26.5 19.3 31.1 28.9 24.5 24.1 24.5 104.70 69.80
17.3 18.8 15.7 22.4 22.6 18.5 23.9 19 81.20 54.13
42.9 41.6 26.6 39.1 38.4 33.2 24.6 32.6 139.32 92.88
36.6 33.2 30.7 31.6 33 31.8 24.4 31.2 133.33 88.89
33.1 32.7 36.8 36.3 35.6 35.9 26.4 35.3 150.85 100.57
34.3 34.3 31.4 31.9 33.3 32.2 25.7 32 130.08 88.89
ID GRP Code Status  Area (cm2) Larm
 Area (cm2)
R arm
 Area (cm2)
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 Area (cm2)
R Ribs
 Area (cm2) T
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 Area (cm2)
Total
014 OB DXA Completed 262.5 265.75 139.97 169.19 143.63 61.26 269.8 428.04 409.37 2149.51 278.32 2427.83
015 OB DXA Completed 233.7 235.32 129.83 142.41 138.35 52.74 215.84 372.86 378.94 1899.99 235.32 2135.31
016 NW DXA Completed 175.27 182.57 107.11 122.93 127.8 35.3 230.86 357.44 374.48 1713.76 250.33 1964.09
019 OB DXA Completed 210.16 205.7 151.33 190.28 144.84 32.05 172.84 348.92 343.24 1799.37 233.7 2033.07
020 NW DXA Completed 215.84 218.68 140.38 139.97 133.08 42.19 233.29 392.33 400.45 1916.22 232.07 2148.29
021 NW DXA Completed 243.84 246.68 144.84 146.47 143.63 47.88 283.6 403.93 43.88 2091.49 273.86 2365.35
022 NW DXA Completed 205.29 205.29 95.75 101.02 121.72 38.54 176.08 327.42 329.45 1600.57 277.92 1878.49
023 NW DXA Completed 215.03 202.05 119.69 123.74 127.8 58.83 238.16 389.49 390.3 1865.1 247.49 2112.59
024 OB DXA Completed 247.9 268.99 147.28 128.21 146.87 52.74 246.68 409.78 421.95 2070.39 262.5 2332.89
025 OB DXA Completed 279.54 296.18 172.03 134.7 154.17 64.1 299.42 498.23 484.43 2382.8 251.55 2634.35
027 NW DXA Completed 195.56 214.63 104.68 101.43 127.4 43.41 249.92 377.73 371.64 1786.39 303.48 2089.87
028 NW DXA Completed 182.28 202.89 133.78 114.78 115.99 40.01 250.98 349.6 366.98 1757.3 245.73 2003.03
030 OB DXA Completed 293.42 311.61 105.08 142.67 145.5 77.19 280.49 512.07 539.56 2407.59 266.34 2673.93
031 NW DXA Completed 207.74 221.88 138.22 127.72 134.59 52.14 221.88 356.47 363.75 1824.39 238.86 2063.25
032 NW DXA Completed 198.85 186.32 132.16 117.61 139.03 33.14 246.54 361.32 364.15 1779.12 254.22 2033.34
033 NW DXA Completed 165.71 167.32 119.63 118.82 120.44 35.16 212.59 328.99 318.88 1587.55 237.65 1825.19
034 NW DXA Completed 175.41 183.89 114.38 113.57 115.19 40.42 255.03 335.45 331.01 1664.34 264.73 1929.06
035 OB DXA Completed 280.08 301.91 145.09 143.88 136.2 50.92 234.82 458.72 456.7 2208.34 267.15 2475.49
036 NW DXA Completed 176.62 185.51 89.32 115.19 118.02 37.18 186.72 278.87 295.85 1483.27 261.49 1744.77
037 NW DXA Completed 243.31 263.11 109.12 115.99 121.25 46.88 264.79 368.19 372.64 1905.22 272 2177.22
038 NW DXA Completed 231.99 223.91 133.78 115.59 134.18 50.12 217.84 378.3 358.49 1844.19 249.77 2093.96
039 NW DXA Completed 178.64 187.13 124.89 130.14 124.48 40.01 187.53 348.98 347.98 1669.19 245.33 1914.51
041 OB DXA Completed 247.35 253.41 161.66 152.77 144.29 45.27 217.84 382.34 408.61 2013.53 250.18 2263.71
042 OB DXA Completed 302.31 302.31 168.54 120.84 178.24 69.11 246.54 494.29 484.59 2366.77 244.11 2610.89
% Fat
Android % Fat Gynoid
Fat
Mass/Height
2 (kg/m2)
Fat
Mass/Height
2 M PP
Fat
Mass/Height
2 F PP
Android/Gyn
oid Ratio
%Fat
Trunk/%Fat
Legs
%Fat
Trunk/%Fat
Legs M PP
%Fat
Trunk/%Fat
Legs F PP
Trunk/Limb
Fat Mass
Ratio
Trunk/Limb
Fat Mass
Ratio M PP
Trunk/Limb
Fat Mass
Ratio F PP
33.8 30 8.41 141.34 99.17 1.13 0.97 109.85 127.80 1.04 112.31 139.60
38.8 35.1 10.3 173.11 121.46 1.11 0.9 101.93 118.58 0.92 99.35 123.49
18.4 33 4.55 67.11 48.66 0.56 1 102.15 123.46 0.54 50.80 64.21
41.5 33 12.7 213.45 149.76 1.24 1.22 138.17 160.74 1.4 151.19 187.92
28.7 35 6.7 112.61 79.01 0.82 0.72 81.54 94.86 0.68 73.43 91.28
27.8 27 5.06 85.04 59.67 1.03 0.94 106.46 123.85 0.94 101.51 126.17
19.9 25.8 4.83 71.24 51.66 0.77 0.64 65.37 79.01 0.63 59.27 74.91
34.7 39.9 8.48 112.02 82.57 0.87 0.8 75.76 94.34 0.78 65.93 86.96
30.9 31.7 8.67 145.71 102.24 0.98 0.96 108.72 126.48 1.03 111.23 138.26
34.3 32.6 10.4 174.79 122.64 1.05 0.96 108.72 126.48 0.91 98.27 122.15
26.2 32.6 5.95 100.00 70.17 0.8 0.71 80.41 93.54 0.66 71.27 88.59
18.3 30.6 4.58 76.97 54.01 0.6 0.59 66.82 77.73 0.58 62.63 77.85
37.6 37.7 9.17 143.96 103.03 1.19 1.08 115.76 137.40 1.08 108.54 135.68
40.3 41.1 8.79 0.98 0.86 1.01 0.86 87.84 106.17 1.01 95.01 120.10
21.6 26.1 5.34 89.75 62.97 0.83 0.81 91.73 106.72 0.78 84.23 104.70
32 32.4 5.76 96.81 67.92 0.99 0.88 99.66 115.94 0.91 98.27 122.15
19.7 30 4.8 80.67 56.60 0.66 0.58 65.69 76.42 0.53 57.24 71.14
33.9 31.6 8.69 136.42 97.64 1.07 0.87 93.25 110.69 0.94 94.47 118.09
26.4 33.8 5.39 90.59 63.56 0.78 0.64 72.48 84.32 0.59 63.71 79.19
18.9 22.6 4.25 71.43 50.12 0.83 0.7 79.28 92.23 0.68 73.43 91.28
28.8 37.1 7.57 127.23 89.27 0.77 0.69 78.14 90.91 0.65 70.19 87.25
33.8 34.4 6.81 114.45 80.31 0.98 0.95 107.59 125.16 1.01 109.07 135.57
41.6 35.3 11.9 200.00 140.33 1.18 1.02 115.52 134.39 1.09 117.71 146.31
35.2 32.8 10.7 167.97 120.22 1.07 0.96 102.89 122.14 0.97 97.49 121.86
ID GRP Code Status  Area (cm2) Larm
 Area (cm2)
R arm
 Area (cm2)
L Ribs
 Area (cm2)
R Ribs
 Area (cm2) T
Spine
 Area (cm2) L
Spine
 Area (cm2)
Pelvis
 Area (cm2) L
Leg
 Area (cm2)
R leg
 Area (cm2)
Subtotal
 Area (cm2)
Head
 Area (cm2)
Total
014 OB DXA Completed 262.5 265.75 139.97 169.19 143.63 61.26 269.8 428.04 409.37 2149.51 278.32 2427.83
015 OB DXA Completed 233.7 235.32 129.83 142.41 138.35 52.74 215.84 372.86 378.94 1899.99 235.32 2135.31
016 NW DXA Completed 175.27 182.57 107.11 122.93 127.8 35.3 230.86 357.44 374.48 1713.76 250.33 1964.09
019 OB DXA Completed 210.16 205.7 151.33 190.28 144.84 32.05 172.84 348.92 343.24 1799.37 233.7 2033.07
020 NW DXA Completed 215.84 218.68 140.38 139.97 133.08 42.19 233.29 392.33 400.45 1916.22 232.07 2148.29
021 NW DXA Completed 243.84 246.68 144.84 146.47 143.63 47.88 283.6 403.93 43.88 2091.49 273.86 2365.35
022 NW DXA Completed 205.29 205.29 95.75 101.02 121.72 38.54 176.08 327.42 329.45 1600.57 277.92 1878.49
023 NW DXA Completed 215.03 202.05 119.69 123.74 127.8 58.83 238.16 389.49 390.3 1865.1 247.49 2112.59
024 OB DXA Completed 247.9 268.99 147.28 128.21 146.87 52.74 246.68 409.78 421.95 2070.39 262.5 2332.89
025 OB DXA Completed 279.54 296.18 172.03 134.7 154.17 64.1 299.42 498.23 484.43 2382.8 251.55 2634.35
027 NW DXA Completed 195.56 214.63 104.68 101.43 127.4 43.41 249.92 377.73 371.64 1786.39 303.48 2089.87
028 NW DXA Completed 182.28 202.89 133.78 114.78 115.99 40.01 250.98 349.6 366.98 1757.3 245.73 2003.03
030 OB DXA Completed 293.42 311.61 105.08 142.67 145.5 77.19 280.49 512.07 539.56 2407.59 266.34 2673.93
031 NW DXA Completed 207.74 221.88 138.22 127.72 134.59 52.14 221.88 356.47 363.75 1824.39 238.86 2063.25
032 NW DXA Completed 198.85 186.32 132.16 117.61 139.03 33.14 246.54 361.32 364.15 1779.12 254.22 2033.34
033 NW DXA Completed 165.71 167.32 119.63 118.82 120.44 35.16 212.59 328.99 318.88 1587.55 237.65 1825.19
034 NW DXA Completed 175.41 183.89 114.38 113.57 115.19 40.42 255.03 335.45 331.01 1664.34 264.73 1929.06
035 OB DXA Completed 280.08 301.91 145.09 143.88 136.2 50.92 234.82 458.72 456.7 2208.34 267.15 2475.49
036 NW DXA Completed 176.62 185.51 89.32 115.19 118.02 37.18 186.72 278.87 295.85 1483.27 261.49 1744.77
037 NW DXA Completed 243.31 263.11 109.12 115.99 121.25 46.88 264.79 368.19 372.64 1905.22 272 2177.22
038 NW DXA Completed 231.99 223.91 133.78 115.59 134.18 50.12 217.84 378.3 358.49 1844.19 249.77 2093.96
039 NW DXA Completed 178.64 187.13 124.89 130.14 124.48 40.01 187.53 348.98 347.98 1669.19 245.33 1914.51
041 OB DXA Completed 247.35 253.41 161.66 152.77 144.29 45.27 217.84 382.34 408.61 2013.53 250.18 2263.71
042 OB DXA Completed 302.31 302.31 168.54 120.84 178.24 69.11 246.54 494.29 484.59 2366.77 244.11 2610.89
Est. VAT
Mass (g)
Est. VAT
Volume
(cm3)
Est. V T
Area (cm2)
Lean/Height2
(kg/m2)
Lean/Height2
(kg/m2) M PP
Lean/Height2
(kg/m2) F PP
Appen.
Lean/Height2
(kg/m2)
Appen.
Lean/Height2
(kg/m2) M PP
Appen.
Lean/Height2
(kg/m2) F PP
515 557 107 21.5 113.28 137.82 9.61 108.34 141.12
553 598 115 20.4 107.48 130.77 9.23 104.06 135.54
218 236 45.3 13.7 69.90 85.46 5.77 63.97 83.62
491 531 102 22.9 120.65 146.79 10.3 116.12 151.25
199 216 41.4 15.4 81.14 98.72 6.81 76.78 100.00
275 297 57 17.2 90.62 110.26 7.99 90.08 117.33
226 244 46.8 16.9 86.22 105.43 7.38 81.82 106.96
290 314 60.2 15.5 77.35 95.09 6.78 74.34 97.55
373 403 77.4 21.5 113.28 137.82 9.55 107.67 140.23
492 531 102 22.5 118.55 144.23 10.7 120.63 157.12
206 222 42.7 17.6 92.73 112.82 8.02 90.42 117.77
189 205 39.3 15.5 81.66 99.36 6.59 74.30 96.77
486 525 101 21.8 112.89 137.71 10.3 115.21 150.15
402 435 83.5 15.7 80.10 97.94 6.44 71.40 93.33
173 187 35.8 17.7 93.26 113.46 8.08 91.09 118.65
187 202 38.7 14.3 75.34 91.67 6.35 71.59 93.25
162 175 33.7 15.3 80.61 98.08 6.95 78.35 102.06
333 359 69 21 108.75 132.66 9.62 107.61 140.23
132 143 27.4 15.9 83.77 101.92 7.18 80.95 105.43
316 341 65.5 17.3 91.15 110.90 7.99 90.08 117.33
262 283 54.4 15 79.03 96.15 6.26 70.57 91.92
289 313 60 14.3 75.34 91.67 6.1 68.77 89.57
694 751 144 21 110.64 134.62 9.61 108.34 141.12
657 710 136 22 113.93 138.98 10.1 112.98 147.23
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Appendix B
Institutional Review Board Approval:
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Appendix C
Informed Consent Statement Form:
Appalachian State University
Informed Consent for Participants in
Research Projects Involving Human Subjects
Title of Project: Estimation of body composition via air displacement
plethysmography using measured and predicted thoracic gas
volumes in normal weight and obese adults
IRB Study #: 18-0355
Principal
Investigator: Jonathon Stickford, Ph.D. Email: stickfordjl@appstate.edu
Research Assistants: Jayvaughn Oliver, B.S. Email: oliverjt@appstate.edu
Erica Larson, M.S. Email: larsone@appstate.edu
Dalton Fletcher, B.S. Email: fletcherds@appstate.edu
John Cantu, B.S. Email: cantujw@appstate.edu
This is to certify that I, have been given the
following information with respect to my participation as a volunteer in a program of
investigation under the supervision of Jonathon Stickford, Ph.D. to which Jayvaughn
Oliver, B.S., Erica Larson, M.S, Dalton Fletcher B.S., and John Cantu may be assisting.
1. Purpose of the study:
Obesity has become a large issue in the US. Obesity-related conditions are the second
leading cause of preventable death. Understanding more about obesity is important for
the effective treatment of over 78 million people in the US.
The main objective of this study is to investigate the measurement of body fat  in an
obese population using measured versus predicted values of lung volumes in the Bod
Pod. The measurements will be compared to values of body fat using DXA. The results
from this study could provide further insight on how these measures may agree in an
obese population.
2. Inclusion Criteria: You may participate in the study if the following apply to you:
 Age: 18 – 45 years of age. The reason for the upper cut-off being that older adults are
more likely to present with physical differences that could affect the outcomes of
some measurements.
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 BMI between 18.5 and 24.9, or between 30 and 40.
 Must be a non-smoker or smoked less than half a pack of cigarettes a day over the
course of a year.
 Have no known lung, heart, kidney disease or energy limitations, or exhibit any signs
or symptoms of lung, heart, and kidney disease or energy limitations.
 Interested in participating in the research study.
 Understand written and oral instructions in English.
 Provide informed consent.
 Available during times the data collection are offered.
Exclusion Criteria: You should not participate in this study if any of the following
apply to you:
 BMI between 25 and 29.9.
 Current smoker or previously smoked more than half a pack of cigarettes a day over
the course of a year
 Known lung, heart, kidney disease or energy limitation, or signs/symptoms suggestive
of known lung, heart, kidney disease or energy limitation will exclude you from
participation.
 Pregnant
 Unable to understand written and oral instructions in English.
3. Procedures: Please read the descriptions of each step in the experiment and write your
initials in the space provided.
You could be asked to repeat a trial, procedure, or test. This could happen for many
reasons such as equipment failure, power outage, inconclusive test results, etc.
However, you do not have to repeat a trial, procedure, and/or test if you do not wish
to do so.
Below is a timeline showing all visits and experiments which you will complete in this study.
Pre-Screen Visit 1
Screening Question (~10 minutes) Informed Consent & Questionnaires (~40
minutes)
Bod Pod ( ~15 minutes)
DXA ( ~15 minutes)
…
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________ initial Prescreen: You may be telephoned by the Principle Investigator or a
Research Assistant (see page 1) and asked screening questions to determine your eligibility for
the study (~10 minutes).
Visit 1:
________ Initial Consent and Questionnaires: Potential participants who meet inclusion
criteria will be invited to a screening interview within the laboratory located off campus
(Levine Hall). At this screening visit, the study will be explained in detail to you by the PI or
a trained research assistant. You will have time to consider your options and get all questions
answered - if you agree to participate, you will then provide your written informed consent.
After you have provided consent (~15 minutes), you will be asked to complete questionnaires:
1) a medical history questionnaire (~15 minutes), and 2) a 24 hour health history questionnaire
(~10 minutes).
________ initial Bod Pod: After completing the questionnaires, we will measure your
height, weight, and body composition. Your percent body fat will be measured using the Bod
Pod. You will sit in a chamber and may hear some clicking while air pressure changes to
measure your body volume. This piece of equipment estimates your body’s composition of
fat and fat free mass by air movement. This is accomplished by measuring your mass and
body volume which is then us to calculate fat mass and fat free mass. This is an extremely
accurate method and presents no risk. These procedures will take ~15 minutes total.
________ initial DXA: A DXA is a type of X-ray used to measure bone strength. During
this test, X-ray pictures of your body will measure how much fat and muscle are present. You
will lie flat on a table and a machine will take pictures of different areas of the body. This test
will last about 15 minutes.
3. Discomforts and risks:
There are minimal risks involved with measuring/monitoring/performing: questionnaires,
physical characteristics, and body composition.
DXA: The risks associated with a DXA scan include exposure to small amounts of radiation.
DXA scanning uses radiation to obtain an image of your body.  Everyone receives a small
amount of unavoidable radiation from the environment each year. Some of this radiation
comes from space and some from naturally-occurring forms of radioactive water and
minerals. The DXA scan technique gives your body the equivalent of about 4 extra days’
worth of this natural radiation. The radiation dose we have discussed is what you will receive
from this study only and does not include any exposure you may have received or will
receive from other tests.  If you are pregnant or trying to get pregnant, you should not
participate in a DXA scan
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Loss of Confidentiality: Any time information is collected; there is a potential risk for loss of
confidentiality. Every effort will be made to keep your information confidential; however,
this cannot be guaranteed.
Other Risks: There may possibly be other side effects that are unknown at this time. If you
are concerned about other, unknown side effects, please discuss this with the researchers.
How you can help reduce some of the risks: During your participation in this research, the
researchers will closely observe your testing to determine whether there are problems that
need medical care.  It is your responsibility to do the following:
• Ask questions about anything you do not understand.
• Keep appointments.
• Follow the study researchers’ instructions.
• Let the researchers know if your telephone number changes.
• Tell the researchers before you take any new medication.
• Tell your regular doctor about your participation in this research.
• Talk to a family member or friend about your participation in this research.
4.    a. Benefits to me: You will receive a copy of your body composition. These screenings are
being performed only for research purposes and are not to be understood as a clinical
screening intended for diagnostic or therapeutic purposes. The screening data will not be
read for any health care or diagnostic purpose. Under no circumstance will the investigator,
research staff or other University employee interpret your screening as normal or abnormal
and they are unable to make any medical comments or interpretations based on your results.
Please contact your health care provider if you have any questions regarding this data.
b. Potential benefits to society: The results of this study could alter the standard protocols
used to measure body fat % using a Bod Pod.
5. Alternative procedures that could be utilized: Not participating in the study.
The procedures used in this study are frequently used in research and are the most
appropriate methods to accomplish the goals of this research.
6. Time duration of the procedures and study:
________ initial Pre-screening (about 10-15 min).
You will need to visit the laboratory for the following:
________ initial Visit 1 (about 1.5 hours).
Approximately 2 hours Total
7. Statement of confidentiality: Volunteers are coded by an identification number for
statistical analyses. All records are kept in a secure location. All records associated with
your participation in the study will be subject to the university confidentiality standards
and in the event of any publication resulting from the research no personally identifiable
information will be disclosed. The Office of Human Research Protections in the U.S.
Department of Health and Human Services, the Office for Research Protections at
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Appalachian State University and the Institutional Review Board may review records
related to this project.
8. Right to ask questions: Please contact Jonathon Stickford, Ph.D. (828-262-7471), with
questions, complaints, or concerns about this research. If you have any questions about
your rights as a research subject, please contact the IRB Administrator at the Appalachian
State University Institutional Review Board Office at (828) 262-2692, irb@appstate.edu.
This study has been approved on February 23, 2019 by the Institutional Review Board
(IRB) at Appalachian State University.  This approval will expire on February 22, 2020
unless the IRB renews the approval of this research.
9. Injury Clause: In the unlikely event you become injured as a result of your participation
in this study, standard emergency procedures will be followed. If you get hurt or sick
when you are not at the research site, you should call your doctor or call 911 in an
emergency. If your illness or injury could be related to the research, tell the doctors or
emergency room staff about the research study, the name of the Principal Investigator,
and provide a copy of this consent form if possible. Please call the PI as soon as possible
(Jonathon Stickford, Ph.D. 828-262-7471). It is the policy of this institution to provide
neither financial compensation nor free medical treatment for research-related injury.
You will be responsible for any costs for medical care not paid by your insurance
company. No other compensation is offered by Appalachian State University.  By signing
this document, you are not waiving any legal rights that you have against Appalachian
State University for injury resulting from negligence of the University or its investigators.
10. Voluntary participation: Your participation in this study is voluntary. You may withdraw
from this study at any time by informing the research personnel. You may decline to answer
certain questions and may decide not to comply with certain procedures. However, your
being in the study may be contingent upon answering these questions or complying with
the procedures. The researcher may end your role in the study without your consent if the
researcher deems that your health or behavior adversely affects the study or increases risks
to you beyond those approved by the Institutional Review Board and agreed upon by you
in this document. You have been given an opportunity to ask any questions you may have,
and all such questions or inquiries have been answered to your satisfaction.
You must be 18 years of age or older to take part in this research study. If you agree to take
part in this research study and have read the information outlined above, please sign your
name and indicate the date below.  You will be given a copy of this signed and dated
consent form for your records.
______________________________________________
Volunteer Date
I, the undersigned, have defined and explained the studies involved to the above volunteer.
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______________________________________________
Person Obtaining Consent Date
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Appendix D
Telephone Screening Form:
Initial Telephone Screening Form for Study
VTG
VTG
We are conducting a study to examine the effect of lung volumes on measurements of
body composition. We will do a series of measurements using the Bod Pod and DXA
where we will analyze resultant measures of body composition. Effort for each of these
tasks will be minimal. This screening is meant to determine if you are eligible to
participate in the study. Basic demographic information will be asked along with a brief
health history. If you choose not to participate, or do not qualify for the study, all of this
information will be shredded. Are you interested in about learning more and potentially
participating in this study?
Great! Well to begin I would like to ask you some general Information:
What is your name, age, and year or birth?
What Gender do you identify as?
May I have your contact information to reach you when necessary, like your email and phone
number?
To the best of your knowledge what is your height and weight?
Do you have any allergies to latex?
Do you currently smoke tobacco or electronic cigarettes?
Have you ever been diagnosed with a sleep disorder or use CPAP?
Do you have a history of asthma, COPD, or any lung issues?
Do you have a history of an irregular heartbeat or any heart condition? (Have you had an
EKG performed?)
Do you have any known health conditions?
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High blood pressure?
Diabetes?
Thyroid issues?
Are you pregnant?
Thank you for taking the time to complete this screening questionnaire.
Based on the information that you have provided we would like to invite you to the lab
to potentially participate in this study. Upon arrival, you will be provide with further
details of the study, and provided your consent we will continue to move forward.
Thank you for your time.
Based on the information you have provided, you do not qualify for this study. I am
sorry about this, but I encourage you to continue pursuing research. Thank you for
your time and have a great day.
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Appendix E
Medical History Form:
Appalachian State University – Integrative Human Physiology Laboratories
251 Industrial Park Dr. Boone, NC 28607 Phone : (828)262-7471
ASU Medical History Form Page 1
Subject ID#: Study:
Highest Education Achieved:
Ethnicity:
Hispanic or Latino. A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish
culture or origin, regardless of race. The term "Spanish origin" can be used in addition to "Hispanic or Latino."
Not Hispanic or Latino.
Race: What race do you consider yourself to be?
American Indian or Alaska Native. A person having origins in any of the original peoples of North, South, or
Central America, and who maintains a tribal affiliation or community attachment.
Asian. A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian
subcontinent, including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine
Islands, Thailand, and Vietnam. (Note: Individuals from the Phillippine Islands have been recorded as Pacific
Islanders in previous data collection strategies.)
Black or African American. A person having origins in any of the black racial groups of Africa. Terms such as
"Haitian" or "Negro" can be used in addition to "Black" or "African American".
Native Hawaiian or Pacific Islander. A person having origins in any of the original peoples of Hawaii, Guam,
Samoa, or other Pacific islands.
White. A person having origins in any of the original peoples of Europe, the Middle East, or North Africa.
Check here if you do not wish to disclose any or all of the above information.
Medications: include over the counter drugs/oral contraceptives/dietary supplements
Name/Dosage/How often taken:
Allergies:
Smoking History:
Do you smoke? Yes No Cigarettes? Pipe / Cigar? Other? If you quit, what year did you quit
# packs per day for # of years What year did you start smoking?
Have you ever been exposed to second hand smoke? Home Work Other Years
Alcohol Consumption History:
Do you currently drink alcohol? If you drank alcohol previously, when did you stop?
If you ever did drink alcohol, what is (was) the volume consumed?
# ounces / day for # of years
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ASU Medical History Form Page 2
Medical History:
NO YES Please explain any "YES" answers below:
high blood pressure
swelling
chest pain / history of heart attack
extra heart beats, racing or fluttering
abnormal electrocardiogram (ECG)
other heart trouble (e.g. murmur, valve problems)
high cholesterol
diabetes (e.g. frequent urination and abnormal thirst)
seizures
stroke
fainting or black-out spells, dizziness
anxiety (diagnosed)
depression (diagnosed)
recurrent fatigue (e.g. feeling tired or extreme lack of energy)
insomnia or poor sleeping
thyroid problems
difficulty breathing
emphysema/ asthma/ chronic bronchitis
cough, sputum (phlegm)
tuberculosis
chronic infection
stomach/GI problems (e.g. heart burn, nausea, vomiting, diarrhea, constipation, abdominal pain, gas pain,
black stools, blood in stools)
hepatitis
bleeding disorder (e.g. bleeding or bruising easily)
kidney/ urinary problems (e.g. frequent urination, burning when urinating, urine changing in color)
joint injuries/ joint pain, back pain, or leg pain
arthritis (rheumatoid or osteoarthritis)
hearing problems (e.g. impaired hearing or ringing in the ears)
migraine headaches
vision problems (exclude corrected near/far sightedness)
surgical procedures (e.g. c-sections, appendectomy, augmentations, knee and back surgeries,
tonscillectomy, etc)
Additional Notes:
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ASU Medical History Form Page 3
Exercise History:
Do you currently exercise aerobically? How many years? Duration:
Types of Exercise: Frequency:
Do you compete in endurance events? How many years? Frequency:
What events? Athlete in college? Yes No
Any other types of exercise? How many years? Duration:
Types of Exercise: Frequency:
If you are currently sedentary, when did
you last exercise?
How many years? Duration:
Types of Exercise: Frequency:
Weight History:
If overweight, how long have you
been overweight?
Were you overweight as a child? By how much?
How many times has your weight changed?
Any events that led up to your obesity? (E.g. Pregnancy, injury) Yes No If yes, how may events? 1  2  3  4  5 >5
Sleep History:
Have you ever been diagnosed with a sleep disorder? Yes No
Do you use CPAP/BIPAP at night? Yes No
Do you snore at night? Yes No
Has someone ever told you that you snore at night? Yes No
Do you have daytime sleepiness? Yes No
Women Only:
Menstrual history: Age begin Regular? □ Yes □ No
□ Heavy □ Medium □ Light
If your periods are irregular or associated with excessive bleeding or unusual discharge please elaborate:
Number of days between periods: days Usual duration of period: days
At what age did menopause occur, if applicable?
Number of pregnancies? Number of births? Explain any complications with pregnancy:
Are you currently Pregnant?
Authorization to Release Information - Please check all that applies and sign/date.
I authorize Appalachian State University to collect and save the above protected health information on
me for purposes of research. I understand that all information is private and confidential.
I authorize Appalachian State University to keep this information and any information gained from my
participation in their studies in a database so that they may contact me.
The above information is correct and complete to the best of my knowledge.
Signature Date
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Appendix F
24-hour Health History Form:
24-HOUR HEALTH HISTORY
Study: VTG YOB: ____________ Height: ____________ Weight: ____________ Sex: ____________
Subject Number: _______________________________ Date: ______________
Do you have:
Head cold
Nasal Congestion
Headache
Sore Throat
Digestive Upset
Intestinal Disorder
General Fatigue
Muscle Soreness
Yes         No
 
 
 
 
 
 
 
 
How do you
feel?
Good
Fair
Not so good
Bad
# of hours sleep_______
How was your sleep?
Normal
Wakeful
Restless
# of hours since eating:_________
What did you eat?
________________________________
________________________________
________________________________
________________________________
________________________________
Medicine taken in last
24 hours:
________________________
________________________
________________________
________________________
Any leg cramps
Since last
activity?
Yes No
 
Physical activity in last 24 hours:
___________________________________
___________________________________
___________________________________
___________________________________
Any unusual physical activity in last
24 hours?
________________________________
________________________________
________________________________
________________________________
** Take weight with each visit.
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24-HOUR HEALTH HISTORY
Study: VTG YOB: ____________ Height: ____________ Weight: ____________ Sex: ____________
Subject Number: _______________________________ Date: ______________
Do you have:
Head cold
Nasal Congestion
Headache
Sore Throat
Digestive Upset
Intestinal Disorder
General Fatigue
Muscle Soreness
Yes         No
 
 
 
 
 
 
 
 
How do you
feel?
Good
Fair
Not so good
Bad
# of hours sleep_______
How was your sleep?
Normal
Wakeful
Restless
# of hours since eating:_________
What did you eat?
________________________________
________________________________
________________________________
________________________________
________________________________
Medicine taken in last
24 hours:
________________________
________________________
________________________
________________________
Any leg cramps
Since last
activity?
Yes No
 
Physical activity in last 24 hours:
___________________________________
___________________________________
___________________________________
___________________________________
Any unusual physical activity in last
24 hours?
________________________________
________________________________
________________________________
________________________________
** Take weight with each visit.
Last Menstrual Period (LMP):  __________________________
(1st Day of LMP)
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